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Lunge kreft og samtidig opptredende sykdommer 
I Norge ble det i 2010 diagnostisert 2826 lungekrefttilfeller. Ved utgangen av 2010 levde 16% 
av kvinner og 11% av men  som fikk diagnosen lungekreft lenger enn 5 år. Som oftest 
diagnostiseres lungekreft i et såpass langt kommet stadium at helbredende behandling ikke 
lenger er mulig. Tidlig diagnostikk av lungekreft er derfor viktig for å kunne tilby flere 
pasienter en behandling som kan gjøre dem friske eller gi langtidsoverlevelse. 
Gjennomsnittlig alder ved diagnosetidspunkt er ca. 70 år, og derfor har mange av pasientene 
med lungekreft andre sykdommer i tillegg. Noen sykdommer opptrer hyppig hos pasienter 
med lungekreft. Man kan spørre seg om det er ren tilfeldighet eller om det kan være en direkte 
sammenheng. Videre er det uavklart om samtidig opptredende sykdom kan påvirke utvikling 
av og overlevelse ved lungekreft.  
Denne avhandlingen har som målsetning å besvare følgende spørsmål: 
• Påvirker andre sykdommer overlevelsen hos pasienter med lungekreft? 
• Påvirker andre sykdommer risikoen for å utvikle lungekreft? 
Det første forskningsspørsmålet ble undersøkt hos pasienter med lungekreft med og uten 
diabetes mellitus. Vi fant at pasienter med lungekreft og diabetes mellitus lever lenger enn 
pasienter med lungekreft som ikke har diabetes mellitus. 
Det andre forskningsspørsmålet ble undersøkt ved å studere en mulig sammenheng mellom 
beintetthet og opptreden av lungekreft, og videre ved å undersøke en eventuell sammenheng 
mellom hjerte-kar-sykdom og opptreden av lungekreft. Personer med lav bentetthet hadde en 
høyere risiko for lungekreft i forhold til personer med normal bentetthet.  
Vi fant videre at personer som røyker og har hjerte-kar-sykdom har en høyere risiko for 
lungekreft uavhengig av røykemengde. 
Avhandlingen viser at samtidige sykdommer kan ha betydning for risiko for å utvikle 
lungekreft og for overlevelse hos pasienter med lungekreft. 
 
 
Kandidatens navn: Peter Hatlen 
Institutt:  Institutt for sirkulasjon og bildediagnostikk 
Veiledere: Tore Amundsen, Arnulf Langhammer, Bjørn Henning Grønberg, Sven 
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4. Background 
 
4.1. Lung cancer 
 
4.1.1. Epidemiology and etiology 
4.1.1.2. Epidemiology 
Lung cancer has the second highest incidence and the highest mortality of all malignant 
diseases. 
 
Incidence 
In the western world male lung cancer incidence rate has increased until 1996, has been stable 
to 2006, and is now decreasing. In women the incidence rate is still increasing. Women 
started smoking later compared with men and the proportion of men who smokes has 
decreased from 1960, while the proportion of smoking women was increasing until 1970 and 
is now stable.  
Today lung cancer has the second highest cancer incidence in men after prostate cancer and 
the second highest in women after breast cancer, Figure 1 (table 1). 
Before 2010 squamous cell carcinoma (SQCC) was the dominating histology of lung tumors, 
but thereafter adenocarcinoma became the most common histology. In the last ten years more 
women and more never-smokers developed lung cancer [1]. The reasons for the changes are 
not clear. However, the incidence of lung cancer in men is decreasing and plateauing in 
women is most probably related to the smoking habit, with less daily smokers, in the western 
world. Another fact that is supporting the smoking theory is that the smoking related SCLC is 
also decreasing. The rise in adenocarcinoma is absolute and relative, it is less smoking related 
Lung cancer – influence of comorbidity on incidence and survival. The Nord-Trøndelag Health study.  
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than SQCC and SCLC, but other explanations are to date not revealed. In contrast, in other 
countries like China, Korea or several countries  in Africa we see increasing portions of daily 
smokers and lung cancer shows an increasing incidence [2]. Also the tobacco-products have 
changed, now more filtered cigarettes that causes lower nicotine content and deeper inhalation 
are used [3]. 
The reduction in prevalence of smoking and change in tobacco products can therefore be 
expected to lead to a further decrease in the incidence of lung cancer over time. 
 
Figure 1: Time trends in age-standardized rates in Norway for selected cancers (semi-
log scale), Source Cancer registry of Norway (CRN) 
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Table 1: Average annual numbers of new cases of lung cancer and age-adjusted 
incidence rates for lung cancer in the period 1971 to 2010, separately for males and 
women (Norway), Source: CRN. 
Average annual number of new cases of lung cancer in the period 1971 to 2010 for males 
1971-75 1976-80 1981-85 1986-90 1991-95 1996-
2000 
2001-05 2006-
2010 
        
679 876 1056 1160 1229 1288 1397 1507 
        
Average annual number of new cases of lung cancer in the period 1971 to 2010 for females 
1971-75 1976-80 1981-85 1986-90 1991-95 1996-
2000 
2001-05 2006-
2010 
        
165 213 303 423 548 702 880 1139 
        
Age-adjusted (world) incidence tares per 100000 person-years for lung cancer in the period 
1971 to 2010 for males 
1971-75 1976-80 1981-85 1986-90 1991-95 1996-
2000 
2001-05 2006-
2010 
        
23.7 28.8 33.2 35.3 36.5 36.6 36.6 35.8 
        
Age-adjusted (world) incidence tares per 100000 person-years for lung cancer in the period 
1971 to 2010 for females 
1971-75 1976-80 1981-85 1986-90 1991-95 1996-
2000 
2001-05 2006-
2010 
        
5.1 6.3 8.7 11.7 15.1 18.8 21.6 25.1 
 
  
Survival 
Data from the Cancer Registry of Norway (CRN) show that the overall survival in lung 
cancer patients is rather short and has changed only marginally the last three decades, five 
years survival after diagnosis was 16% in women and 11% in men in the end of 2010 in 
Norway. The overall survival in men has changed from 1971 – 1975 to 2006 – 2010 from 8% 
to 11%. In women it has improved from 10% to 16% [4]. The highest improvement in 
survival has been observed in cases where the disease has been detected and treated in early 
stages. In men the survival has increased from 19.2% to 41.4% for localized disease, in 
female from 27.2% to 50.5% in the period 1971 to 2010, respectively [2].  
Lung cancer – influence of comorbidity on incidence and survival. The Nord-Trøndelag Health study.  
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Figure 2: Survival rates, stratified by stage, for men and women from 1974 to 2009. 
 
 
 
Survival rates varied more among the histological sub groups. The poorest survival is seen in 
patients with SCLC (5% 5 years survival rate and 2% 10 years survival rate). In contrast, the 
10-year relative survival rate for patients with lung sarcomas was 18%. Patients with 
adenocarcinoma of the lung had a better 5 years survival rate (10%) than patients with other 
sub groups of histology. Surgical candidates diagnosed with Stage I squamous cell carcinoma, 
adenocarcinoma, and large cell carcinoma had 5-year relative survival rates of 55– 63%. The 
prognosis for patients with SCLC was poor under any conditions, but patients treated with 
both chemotherapy and radiation therapy had longer survival than patients treated with 
chemotherapy alone at every clinical stage of disease. 
  
4.1.1.3. Etiology of lung cancer 
1: Tobacco smoking is regarded as the main cause of lung cancer. 90% of all patients 
with lung cancer have a positive smoking history [5].  On the contrary, of smoking persons 
Lung cancer – influence of comorbidity on incidence and survival. The Nord-Trøndelag Health study.  
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there are rather few that develop lung cancer. Smoking is probably not alone sufficient to 
develop lung cancer. In Norway there has been a decrease in the prevalence of daily smokers; 
in 1973 51% of males and 32% of women were daily smokers, whilst in 2010 17% of both 
sexes were daily smokers (figure 3) [6].  
2: But also secondhand smoking is an important cause of lung cancer. Approximately 
15% of lung cancers in never smokers are accounted to passive smoking [7, 8].  
3: Occupational and every-day exposure to radon (in our environment) is regarded as a 
risk factor for lung cancer [7]. Occupational exposure to asbestos increases the risk of lung 
cancer, especially in case of concomitant tobacco smoking, where the risk increases in a 
multiplicative way [7, 9, 10].  
4: A family history of lung cancer in a first-degree relative is associated with a higher 
risk of lung cancer, independent of smoking [11].  
5: People who received radiotherapy for other diseases are at a higher risk for lung 
cancer [12].  
6: COPD is also known as an independent risk factor for lung cancer.  
 
Figure 3: Fraction of daily smokers among men and women in Norway from 1927 to 
2007, Source: CRN. 
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Chronic inflammation has been documented to influence risk for LC through increased cell 
turnover with the potential of generating genetic errors, as well as stimulating angio-
neogenesis and apoptosis [13, 14]. The fact that the use of inhaled corticosteroid reduces the 
risk of lung cancer support this theory [15, 16]. 
Some factors seem to protect against lung cancer. Higher physical activity reduces the risk of 
lung cancer [17] and aspirin may reduce the risk of lung cancer [18]. 
 
4.1.2. Histological classification of lung cancer 
The World Health Organisation (WHO) has published the current recommendation for the 
classification of malignant lung tumours [19]. 
Lung cancer has the last decades primarily been divided in NSCLC and SCLC. NSCLC is 
further sub-classified into adeno-, squamous cell-, adenosquamous and large cell carcinomas, 
and NOS (not otherwise specified). The last category has the poorest 5-year survival estimates 
(5.8%) as well as a median overall survival (OS) of 5 months [20]. SCLC is sub-classified 
into oat cell cancer and combined small-cell cancer. For more detailed classification se (table 
2). 
However, many lung cancers consist of a mixture of histological subtypes. The portion that is 
most differentiated defines the final histological diagnosis, except for tumors containing 
SCLC which is described as SCLC independent of the other histological components. The 
most important classification is however the division in SCLC and NSCLC with it sub-types 
(table 1), because it is a premise for choosing therapy, and for individualized treatment. 
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Table 2: WHO guidelines for histologic classification of lung cancer 
Tumour type Tumour subtype 
Non-Small-Cell Lung Cancer Adenocarcinoma 
 Squamous cell carcinoma 
 Adenosquamous carcinoma 
 Carcinomas with pleomorphic, sarcomatous characteristics, 
 
 Carcinoid 
 Carcinomas of salivary gland origin 
 Not otherwise specified 
Small-Cell Lung Cancer Oat cell cancer  
 Combined small-cell 
 
The different histology subgroups in lung cancer have changed during the last decades. The 
proportion of SCLC and SQCC (squamous cell carcinoma) is decreasing in both sexes (more 
prominent in men), probably due to less daily smokers. Adenocarcinoma is increasing in both 
sexes (more prominent in women) [21]. Figure 4 shows the changes of incidence proportions 
of the histological subgroups. 
 
Figure 4: Lung cancer incidence proportion of histological subgroups in males (A) and 
females (B), Source [21]. 
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4.1.3. TNM classification and clinical staging 
Like most other malignant diseases, lung cancer distribution is classified by the TNM 
classification system, based on CT examination. “T” describes the size, invasion in neighbor 
structures and location of the primary tumor, “N” describes possible lymph node involvement 
and localization and “M” describes the presence and localization of metastases. This TNM 
classification was established in the 1940s and for lung cancer the latest is the seventh edition 
published in 2009 [22]. The clinical staging and histology of NSCLC and SCLC are crucial 
estimating prognosis and for the choice of therapy, curative versus palliative treatment (table 
3 and figure 5). 
Stage Ia - IIb are defined as localized, IIIa - IIIb as locoregional and stage IV as advanced 
disease. All patients with suspected lung cancer should undergo a computer tomography (CT) 
scan of the thorax and the upper abdomen. In patients with probably limited SCLC and 
NSCLC based on CT, a CT caput or Magnetic resonance tomography (MR) caput and 
positron emission tomography CT (PET-CT) are taken to assess if it is really limited or loco 
regional or advanced disease, before the final evaluation if it is eligible for curative treatment. 
Based on the imaging results showing probably N2-3 disease, invasive EBUS (endo bronchial 
ultra sound) or subsequent mediastinoscopy are performed to further differentiate between 
Lung cancer – influence of comorbidity on incidence and survival. The Nord-Trøndelag Health study.  
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tumor positive or negative lymph nodes (for the definition of the final clinical stage)  Further 
description of classification and clinical staging are not the scope of this thesis. 
 
Table 3: Lung cancer stage groups according to TNM [22] 
 
 
 
4.1.4. Treatment of lung cancer 
Choice of treatment depends on tumor factors like histology, TNM classification, clinical 
stage and host factors like comorbidity, and heart-lung function, and to a lesser degree on age. 
In clinical stage I-II, T1aN0M0 to T2bN1M0, curative surgery is recommended for NSCLC; 
and 30-70% of these patients will live longer than 5 years, depending on the specific clinical 
stage. If the patient is not medically fit for the surgery, a less traumatic treatment option is 
stereotactic body radiation therapy (SBRT). This leaves the patients with a lower overall 
survival rate than surgery. In stage I radical surgery alone is considered sufficient as treatment 
and in stage II, if no contraindications, adjuvant chemotherapy is indicated, and increases the 
Stage Ia 
Stage Ib 
Stage IIa 
Stage IIb 
Stage IIIa 
Stage IIIb 
Stage IV 
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5-years overall survival 4-10% in this group [23]. Stage III SCLC and NSCLC stage IIIA-N2 
disease, loco-regional disease, is a heterogenic group of lung cancer and should be evaluated 
for semi-curative treatment, radio-chemo therapy with or without surgery and about 20-30% 
of the patients will live longer than 5 years. The more advanced locoregional stage IIIB 
disease may in some cases be treated with radio-chemotherapy leading to a 5 years OS of 10-
15%. Even more advanced stage IIIB and stage IV disease are offered chemotherapy alone 
with palliative intention. These patients do not have a curable disease and the overall survival 
is 8-10months with therapy, and 4-6 months without therapy. But, the group is heterogeneous 
both in disease distribution and prognosis and the survival varies substantially. 
  
4.1.4.1. Individualized treatment in patients with lung cancer 
During the last years individualized treatment based on histological subgroups and molecular 
analyses of the receptor structure at the cell membrane has been up-coming. Future lung 
cancer treatment will probably be even more individualized, based on gene molecular 
characteristics of the tumor cell involved. 
To date, the most therapeutically important mutations in molecular mapping for personalized 
and optimized lung cancer treatments are: 
 
(1) The Epidermal growth factor receptor (EGFR) mutation (detected by PCR, IHC or FISH), 
which is more common in adenocarcinomas, never-smokers, women and persons from Asia, 
and is found in about 8% of NSCLC patients in Norway 
(2) The EML4-ALK fusion (detected by PCR, IHC or FISH), which is present in 
approximately 3 to 6 percent of adenocarcinomas and is also more common in people who 
have never smoked.  
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(3) The KRAS mutation (detected by PCR, IHC or FISH), which is more common in past or 
current smokers.  
 
Epidermal growth factor mutations were among the first biomarkers shown to have 
therapeutic implications, other biomarkers are being evaluated in clinical trials [24-26]. 
Three pharmacological agents are registered and approved for use in Norway in patients with 
detected DNA mutation or particular proteins in the tumor: crizotinib, gefitinib and erlotinib 
and we are waiting for afitinib.  
Individualized treatment is also a challenge for the health care personal, new knowledge, 
ongoing studies and a good collaboration between pulmonologists and pathologists is 
required. 
 
4.1.5. Screening for lung cancer 
Local lung cancer disease detected more accidentally on imaging for other reasons are often 
presenting without symptoms, and has a god survival rate when early treated. This fact 
emphasizes the importance of early detection and treatment of lung cancer, at a localized 
stage when curative treatment by surgery or stereotactic radiation is possible, Thus, around 
the world there is a lot of attention and effort made in order to characterize the population at 
highest risk of getting lung cancer, to find the most cost-effective screening procedure and 
offering the people with localized disease curative treatment, including surgery and 
stereotactic radiation.  
Up to date, known risk factors like tobacco smoking, age above 50 years and COPD has been 
studied as relevant factors in screening for lung cancer, especially for inclusion in large trials 
using CT imaging, but the question about cost-effectiveness has to be settled [27, 28]. Until 
then, research groups are hunting for new and relevant risk factors for lung cancer, to improve 
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the characterization of the population at risk. Detecting new risk factors may also open 
possibilities for early prevention or treatment of the condition of interest. 
Screening is defined as a systematic testing of individuals who are asymptomatic but have a 
higher risk for a specific disease [29] dependent on one or more detectable risk factors, like 
newborn screening.  
In 1968 the WHO published the document “PRINCIPLES AND PRACTICE OF 
SCREENING FOR DISEASE” written by Wilson and Junger [30] (table 4). 
 
Table 4: The Wilson criteria for screening 
 
The purpose of screening is to prevent, interrupt or delay the development of a certain 
disease. In cancer disease it is important to detect the disease before metastases have 
developed. In general, screening must lead to better outcomes regarding lung cancer or overall 
survival, being easy and gentle to perform for all person defined being at risk, to a cost-
effective price.  
The screening technique must be sensitive enough to identify most cases and must be specific 
enough to avoid an excess of unnecessary investigations, treatments and patient’s worries. 
The most widely used endpoint in studies investigating the benefit of screening is disease-
specific mortality [31]. 
At the moment, in Norway established screening programs are used for breast cancer and 
cervix cancer. A pilot study for colon cancer screening started in 2012 in Norway. 
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A discussion about the cost-effectiveness of screening for lung cancer is still ongoing.  
Most screening tests are non-invasive, however some involve procedures that may cause 
complications [32]. Because of increased risk for comorbidities among long time and heavy 
smokers, complications associated with invasive diagnostic procedures and therapy may be 
more frequent in these groups. Further, screening can cause anxiety and worries as well as 
further unnecessary procedures to check false positive results [33]. On the other hand, false 
negative results may lead to ignorance of symptoms and delayed diagnosis. 
In lung cancer screening different strategies have been investigated in clinical trails, like 
Chest X-ray, Chest X-ray with sputum histology and low dose spiral CT.  
Repeated chest x-ray with and without sputum histology has not been shown to reduce the 
mortality in lung cancer and is consequently not recommended as screening methods for lung 
cancer [34, 35]. Therefore CT scan was introduced as a possible screening method in lung 
cancer [31], like the National Lung cancer Screening Trial (NLST), The Prostate, Lung, 
Colorectal and Ovarian (PLCO) Cancer Screening Trial, Dutch-Belgian Randomized Lung 
Cancer Screening Trial (NELSON), DANTE trial and the Danish Randomized Lung Cancer 
CR Screening Trial.  
The National Lung cancer Screening Trial (NLST) showed a 20% reduced relative mortality 
of lung cancer [36] while the PLCO trial did not show any reduction of mortality [37].  The 
Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON) showed a reduced 
mortality, however the DANTE trial and the Danish Randomized Lung Cancer CR Screening 
Trial did not show any mortality reduction.  
At the moment, screening with low dose CT scan is not recommended in lung cancer 
screening [38, 39] in general, with an exception for US where they follow the NLST criteria 
in the regions with access to the same clinical expertise as in the study. Also in Norway 
screening for lung cancer is not recommended at the time. 
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75% of the patients with lung cancer are not curable at the time of diagnosis [40]. Survival in 
patients with NSCLC is directly related to the stage of the disease at the time of diagnosis and 
varies from above 50% (stage IA) to 0% (stage IV) 5 years survival (figure 5). Corresponding 
estimates are limited for SCLC, but it is reason to expect that survival is related to stage 
(limited vs. extended disease) for this type as well. Possibly, screening can save lives in 
selected groups (high risk persons) based on combined risk scores and this shows the 
importance of finding new risk factors relevant to screen for. 
 
Figure 4: Survival Curves for Patients with Lung Cancer by Stage, source 
http://www.pet-vghks.com.tw/?p=3057 
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4.2. Lung cancer and comorbidities 
 
4.2.1. Definition  
Comorbidity is defined as a coexisting medical conditions or diseases that are additional to a 
primary diagnosis. Comorbidity is more frequent in older patients, and a risk factor may be 
associated to different diseases, which makes causal relation, degrees of association and 
interaction difficult to study. Since the mean age for the debut of lung cancer is 71 years, 
comorbidity is common in patients with lung cancer [41]. 
Another term used is multimorbidity. Multimorbidity and comorbidity are often used 
similarly but by definition comorbidity indicates a condition that coexists with a disease of 
interest (in our study lung cancer) while multimorbidity does not assume that a patient has a 
disease of interest (like in our study lung cancer), but the individuals may of course be at 
higher risk for lung cancer. In one study 99% of women and 97% of men aged 65 years or 
older have had two or more medical conditions [42]. Persons with multimorbidity are more 
likely getting additional coexisting medical condition than persons without multimorbidity 
[43]. Comorbidity, as multimorbidity, can affect treatment choice, prognosis, and survival in 
older people [44].  
 
4.2.2. Comorbidity in patients with lung cancer 
Today in patients with lung cancer, the most frequent concomitant diseases are cardiovascular 
diseases (23%), compared to 10% in the general population at 65 years or older, chronic 
obstructive pulmonary diseases, COPD (22%), compared to 11%  in the general population at 
65 years or older,  (figure 6). Comorbidity is higher in men and in patients with squamous-cell 
carcinoma, probably due to the smoking habit of men [45]. 
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Figure 5: Age-specific prevalence of concomitant diseases for men and women, source 
[45] 
 
 
Comorbidity seems to be associated with earlier diagnosis of lung cancer, but it may also 
leads to less aggressive treatment. Thus the prognosis in patients with lung cancer can be 
negatively influenced by comorbidity [45]. 
 
4.2.3. How to measure comorbidity 
Handling of comorbidities is important in the care of cancer patients but there is no definite 
consensus about how to measure it. The difficulties in measuring comorbidity depend on 
many factors. The importance of different comorbidities vary with the type of cancer [46]. In 
patients with lung cancer the Charlson Index is the most common method to measure the 
existence, burden and consequences of comorbidities [47]. This index was developed by M. 
E. Charlson in 1987 and is based on a point scoring system (from 0 to 40) for the presence of 
one or more associated diseases and taking into account the age of the patient. The advantage 
of the Charlson Index is the capability of evaluating the patient’s mortality risk based on age 
and comorbidity. In the absence of comorbidity the mortality is 12%, at 1–2 points it is 26% 
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at 3–4 points it is 52% and with the accumulation of more than 5 points it is 85% in all stages 
of the disease.  
 
4.2.4. The impact of comorbidity on survival and treatment 
In general comorbidity in patients with lung cancer is associated with decreased survival [48]. 
Studies show that 25% - 40% of the lung cancer patients with comorbidity do not die of the 
cancer itself but because of present comorbidity [49]. The influence of comorbidity on 
survival is most important in patients with early stage of lung cancer disease and is less 
important in advanced lung cancer diseases [50].     
 
The impact of comorbidity on choice of treatment and consequences for survival is still 
unclear. At present there is no consent whether comorbidity in general is a prognostic 
negative factor on survival. In one study, Janssen-Heijnen et al show no association between 
comorbidity and survival [51, 52] while Asmis et al show that the presence of comorbidity is 
associated with a poorer survival [53], and there is at the time no guidelines pointing out the 
impact of comorbidity on the choice of treatment [54].  
 
Medical decisions should incorporate patient’s preferences. Limited evidence for treatment 
choice in older patients with comorbidity, benefits and prognosis can be different in this 
patient group [55, 56]. The complexity of treatment can be different in older people with 
comorbidity and the choice of therapy should be optimize with respect on the quality of life of 
older patients [57]. 
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5. Diabetes mellitus 
 
Diabetes mellitus (DM) is a common endocrine disorder, a metabolic disease with tendency to 
hyperglycemia and is a disorder in the insulin activity or function, either lack of insulin or an 
inadequate effect of insulin on cells, are the two main characterizations. In general two major 
types of DM are present. Type 1(DM-1) is caused by pancreatic beta cell destruction, which 
in the end leads to absolute insulin deficiency. Type 2 (DM-2) is characterized by insulin 
resistance (through changes in the cells’ insulin surface receptors as well as intracellular 
insulin signaling). Initially the body compensate by releasing more insulin to overcome this 
insulin resistance. However, with time a relative insulin deficiency or an insulin secretory 
defect (due to insufficient insulin production in the beta- cells in the pancreas) develops and 
glucose levels start to rise. 
In DM-1, insulin is missing in the circulation and it must be substituted. In DM-2 there are in 
principle two ways of treating the condition. One way is to increase the insulin levels either 
by stimulating secretion of insulin from the pancreas or inject insulin into the patient; the 
other way is to increase the sensitivity of the target cells for insulin. Sulfonylureas, introduced 
in the U.S. in 1955, are a group of pharmaceuticals that increases the insulin secretion from 
the pancreas, and metformin, introduced as treatment for DM in 1958 in the U.K., decreases 
the insulin resistance of the target cells. 
 
5.1. Diabetes mellitus and lung cancer 
 
The insulin resistance plays a central role in DM-2. It leads to higher levels of endogenous 
insulin. Higher insulin levels can leads to an increased mitogen effect in most cells and 
further, it can leads to insulin resistance and higher blood glucose levels that stimulate the 
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insulin like growth factor 1 (IGF-1) secretion. Bioactive IGF-1 has antiapoptotic effect. Both 
mitogen and antiapoptotic effects promote cancer development and cancer growth [58-60]. 
Several studies have showed an increased risk of cancer (breast, large bowel, endometrial and 
pancreatic cancer) in patients with DM [61-65]. Further it is known that insulin and insulin 
analogues have a cell growth promoting activity [66] and may influence the survival in 
patients with lung cancer. 
Some observational studies indicate that metformin used in DM-2 reduces the risk of cancer 
[67], and it may be initiated through the effect of metformin on the AMP-activated protein 
kinase (AMPK) which suppresses cell proliferation in non-malignant as well as in tumor cells 
[68]. An additional effect may be that metformin improves the prognosis in cancer [69]. The 
mechanism for these effects is still not clear and it is also discussed whether metformin 
directly acts with or within the cancer cells [70]. Two studies have shown reduced cancer risk 
associated with use of metformin [71, 72]. There is evidence that insulin may increase the risk 
of lung cancer [73]. 
Few studies have investigated the association between incidence and survival in patients with 
lung cancer and DM. One study showed no increased risk of lung cancer in patient with DM 
[74]. Another study showed that patients with DM and NSCLC had a lower risk getting a 
metastatic diseases but there was no reduction in mortality among lung cancer patient with 
DM [75]. Three studies looked at the survival in patients with lung cancer and DM, 
independent whether DM-1 or DM-2, and the results were conflicting. Two study showed 
increased survival in patients with DM and lung cancer [76, 77]. The other one did not find a 
positive association between DM and survival in lung cancer [78]. 
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5.2. Metformin and lung cancer 
 
Metformin prevents tobacco carcinogen–induced lung tumor genesis in mice [79]. Other 
studies showed that metformin inhibits the growth of lung cancer cells and induces apoptosis 
[80]. However may diabetics using metformin develop a more aggressive cancer phenotype 
[81]. One case-control study from 2013 did not show a decreased risk of lung cancer in 
patients using metformin [82].  
Metformin may also have an indirect effect on lung cancer treatment and may enhance 
radiation response of NSCLC [83]. Further studies are needed to evaluate whether metformin 
is a drug that may be used in lung cancer treatment. 
 
6. Osteoporosis 
 
Osteoporosis, a disease of the bone, is characterized by an abnormal interplay between 
osteoclast and osteoblast function, and leads to fragile bone tissue. Three main factors have a 
central role in developing osteoporosis: An inadequate peak bone mineral at early adult age, a 
high bone resorption and third an inadequate formation of new bone [84]. As early as in 1940 
it was described that estrogen played a central role in the pathogenesis of osteoporosis, and 
during the last decades several studies have confirmed the central role of estrogen. Estrogen 
deficiency increases and estrogen treatment decreases bone remodeling. There are two 
estrogen receptors, ERα and ERβ, which are important for the impact of estrogen on the bone 
formation [85, 86]. 
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6.1. Estrogen and lung cancer 
 
Studies have indicated that estrogen has a central role in lung cancer. Estrogen receptors ERα 
and ERβ have been found in non-small-cell lung cancer tissue [87-89]. The presence of ERα 
and the absence of ERβ are associated with a poorer prognosis among NSCLC patients [90]. 
This could imply that estrogen may promote lung cancer carcinogenesis via estrogen 
receptors. In line with this, studies have found decreased mortality and reduced lung cancer 
cell proliferation in patients treated with anti-estrogens [91, 92]. There is evidence for a sex 
difference in expression of estrogenic receptors in lung cancer [93, 94]. The difference may 
be explained in the different gene location in the tumor cells and the different protein 
expression in the tumor cells.  
 
6.2. Osteoporosis and cancer 
 
Several studies have been performed to evaluate the impact of osteoporosis and low bone 
mineral density (BMD) on the risk of cancer. After our knowledge only one study has 
investigated the association between osteoporosis, defined by the International Classification 
of Diseases (ICD)-10 coding system, and the incidence of lung cancer. Patient younger than 
70 years of age having osteoporosis in general have an increased risk of getting cancer [95]. 
They explain this tendency with the fact that this population are more likely to smoke. 
The association between BMD and other cancer conditions is studied in more details.  
Two studies have shown an inverse relation between BMD and risk of colon cancer [96, 97].  
In two case-control studies on breast cancer no relation between BMD and the risk of breast 
cancer were observed [98, 99]. Another study showed that women with osteoporosis have a 
decreased risk of breast cancer [95].  
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Patients with a low BMD have a reduced risk developing endometrial cancer [95].  
In patients with prostate cancer there are conflicting results. One study shows no association 
[99], one shows that increasing BMD associates with increased risk getting prostate cancer 
[100], and one shows that decreasing BMD associates with an increased risk of getting 
prostate cancer [101].  
 
Osteoporosis is associated with a low level of Vitamin D [102]. In the last two decades 
studies show that vitamin D protects against the development of cancer [103, 104]. This fact 
is strengthened by two studies finding that hypovitaminose D is correlated with a higher 
incidence of lung cancer [105, 106]. Another evidence for the role of vitamin D in lung cancer 
is that the TaqI polymorphism of the vitamin D receptor (VDR) gene might be a risk factor 
for lung cancer [107]. So far there are no evidences that there are a relationship between 
Vitamin D levels and survival [108]. 
  
6.3. BMD and the male skeleton 
 
Sex steroids are important for bone metabolism. Testosterone level decreases only marginally 
with age in men [109]. Epidemiological studies, investigating the association between 
testosterone and BMD found no relationship [110]. An epidemiological study found that 
serum estradiol, but not testosterone, levels was positively associated with BMD in men over 
age 65 year [111]. 
It is well established that estrogen deficiency is associated with low BMD/osteoporosis in 
women.  In the last years different studies confirm these findings, that estrogen plays a key 
role in bone metabolism in men, young and old [112-115]. 
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However, these studies do not exclude an important of testosterone in the male skeleton [116, 
117]. 
 
 
7. Chronic inflammation and cancer 
 
The relationship between inflammation and cancer is widely accepted [13]. Inflammation 
causes tissue injury. This leads to a complex activation of many different reactions, cellular                               
components (neutrophils, macrophages and other inflammatory cells), release of cytokines 
and growth factors [13]. 
Carcinogens can induce somatic changes with DNA mutation. These changes can persist in 
normal tissue until a stimulation or promotor can “activate” these DNA. Those “promotors” 
can be inflammation, hormones, chronic irritation or chemical irritants [118].  
In chronic inflammation inflammatory and phagocytic cells, and their cytokines can induce 
DNA damage in proliferating cells, by the production of reactive oxygen and nitrogen species  
[119]. The presence of reactive nitrogen and oxygen released from inflammatory cells, 
interacts with DNA in proliferative cells which can causes permanent genomic alterations 
such as point mutations, deletions, or rearrangements. 
Cytokines are released in infection and/or inflammation. Normally the cytokines helps in 
handling infection. However, cytokines play also an important role in cancer pathogenesis. 
Tumor invasion, promoting tumor growth, apoptosis and promoting metastases are some of 
the effects of cytokines on tumor cells [120]. 
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8. Risk factors for cardio vascular diseases and the association to 
lung cancer 
 
Chronic inflammation is documented to play a role in the pathogenesis of cardio vascular 
disease (CVD), which is frequently seen in patients with lung cancer, with an influence on all 
stages of the disease [121]. We found no publications on the study of possible association 
between CVD and the incidence of lung cancer. Regarding other factors of influence on both 
CVD and LC; tobacco smoking is a common risk factor, whilst, like hypertension, BMI and 
high cholesterol have been studied in patients with lung cancer. There are evidence that high 
blood pressure may increase the risk of lung cancer in smoking men [122], that hypertension 
increases the lung cancer related mortality in patients with lung cancer [123]. High BMI 
mineral is a known risk factor for CVD [124]. The association between BMI and lung cancer 
is invers. Smokers with a lower BMI are at higher risk getting lung cancer compared with 
smokers with high BMI [125]. High cholesterol is associated with a higher risk of CVD. The 
risk association between cholesterol and lung cancer was investigated in some older studies. 
No association was found between cholesterol and the risk of lung cancer [126, 127]. 
Metabolic syndrome, also a known risk factor for CVD, is associated with an over all 
increased risk of cancer. Most studies investigated this association in patients with colo-rectal 
cancer and pancreatic cancer [128, 129]. There are some results which suggest that there is no 
association between the risk of lung cancer and metabolic syndrome [130]. 
 
With special interest in co-morbidity in lung cancer as described above, access to large 
registries, we decided to design studies to look at their possible influence on lung cancer 
development and survival. 
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9. Aims of the study 
 
The primary aim of the study was to study the possible influence of comorbidities on the 
incidence and survival of lung cancer. 
The secondary aim was to look for new risk factors that may be used in screening trails for 
lung cancer. 
 
10. Material and methods 
 
10.1. Material 
 
The study populations for the three papers were recruited from the Nord-Trøndelag Health 
Study (HUNT study), the Pemetrexed-Gemcitabine Study (PEG) study and the Norwegian 
Lung Cancer Biobank (NLCB) study. 
 
The HUNT study [131] is a large population-based prospective cohort study in Norway 
having collected data in three surveys, HUNT 1 (1984-1986), HUNT 2 (1995-1997) and 
HUNT 3 (2006-2008). Individuals aged 20 years or more were invited each time. In total 77 
205 (89% of invited), 65 233 (69% of invited) and 50 806 (54% of invited) people 
participated in HUNT 1, 2 and 3, respectively. Many people participated two or three times 
which reduces the total number of subjects to approximately 106 000. Nord-Trøndelag is a 
county in the middle of Norway having 130 708 inhabitants in January 2009. This population 
is considered representative of the Norwegian population, but the county lacks larger cities, 
has a lower educational and income level, and the proportion of smokers is slightly below the 
mean in Norway. 
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The PEG study [132] was an open randomized multicenter phase III trial of 436 patients 
with stage IIIB/IV non-small-cell lung cancer by the Norwegian Lung Cancer Group 
(NLCG). The aim of the study was to compare pemetrexed plus carboplatin versus 
gemcitabine plus carboplatin as first line chemotherapy, given as four courses with 3 weeks 
intervals, with respect to health related quality of life, survival and toxicity. The study was 
conducted from April 2005 to July 2006.  
The NLCB, a registry study started March 15th 2006 aiming to collect tumor tissue, normal 
tissue and blood samples from patients consecutively admitted to hospital and suspected to 
have lung cancer. In our study we included only patients with verified lung cancer from the 
NLCB registry study, which included all clinical stages of lung cancer. 
Data from the HUNT study were linked to the Cancer Registry of Norway (CRN) and the 
Norwegian Cause of Death Registry at Statistics Norway (SSB) [133]. In the PEG-study and 
in the NLCB registry data were collected from the electronic patient records. 
The candidate has contributed with data collection in the PEG study and NLCB registry 
study. 
 
10.2. The study population 
 
Study 1 
The main study population was recruited from the HUNT study 1, 2 and 3 [134]. In this 
population we found 1206 cases of lung cancer (table 6). In addition we used 436 cases from 
the Pemetrexed Gemcitabine study (PEG-study) [135]. From the NLCG study 210 patients 
with lung cancer were included.  Only patients with histological verified lung cancer (stage of 
disease I-IV) until October 15th 2010 were included in the study. 
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Table 5: Characteristics of lung cancer patients in the HUNT, PEG and NLCB studies 
by having or not having diabetes mellitus. 
  
 HUNT 
1984-2008 
N = 1206 
PEG 
2005-2006 
N = 436 
NLCB 
2006-2010 
N = 210 
Total 
 
N = 1852 
 DM 
N = 49 
Non-DM 
N = 1157 
DM 
N = 17 
Non-DM 
N = 419 
DM 
N = 18 
Non-DM 
N = 192 
DM 
N = 84 
Non-DM  
N = 1768 
 N % N % N % N % N % N % N % N % 
         
Age (years) 
a 
71.0 ± 
8.2 
70 ± 10.9 73 ± 7.0 64 ± 9.8 68 ± 8.0 68 ± 9.7 70.1 ± 7.7 67.3 ± 10.1 
Gender                 
Male 39 80 749 65 12 70 239 57 10 56 112 58 61 73 1100 62 
Female 10 20 408 35 5 30 180 43 8 44 80 42 23 27 668 38 
Smoking 
history 
                
Never 9 18 182 16 0 0 32 8 0 0 5 3 9 11 219 12 
Ever 40 82 975 84 17 100 387 92 18 100 187 97 75 89 1549 88 
Stage of 
disease  
                
Non-
metastatic 
28 57 507 44 - - - - 8 44 80 42 36 43 587 33 
Metastatic 11 22 520 45 17 100 419 100 9 50 110 57 37 44 1049 59 
Unknown 10 21 130 11 - - - - 1 6 2 1 11 13 132 8 
Histology                  
NSCLC 35 71 806 70 17 100 419 100 14 78 157 82 66 78 1382 78 
SCLC 6 12 201 17 - - - - 3 17 27 14 9 11 228 13 
Unknown 8 17 150 13 - - - - 1 5 8 4 9 11 158 9 
N, number; HUNT, Health Study of Nord-Trøndelag; PEG, Pemetrexed Gemcitabine study; NLCB, Norwegian 
Lung Cancer Bio Bank; LC, lung cancer; DM, diabetes mellitus; NSCLC non small cell lung cancer; SCLC, 
small cell lung cancer 
a Values given as median ± SD.  
 
 
Study 2  
In study 2 only participant from the HUNT 2 study were included (table 7). Participants older 
than 50 years of age, having measured bone density (N=18156), having answered the 
questions on self reported fracture (N=55052) and osteoporosis (N=52804) and known body 
mineral index (BMI) (N=18079), were evaluated for inclusion.  A total of 6996 persons were 
included in the study 2. Among these were 132 cases of NSCLC.  
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Table 6: Baseline characteristics of the study population in study 2 
  Women Men Total 
  N % N % N % 
 Low 1622 34 692 31 2314 33 
BMD z-score Medium 1590 33 774 35 2364 33 
 High 1601 33 747 34 2348 34 
Fractures Yes 1083 23 268 12 1351 20 
 No 3730 77 1945 88 5675 80 
Osteoporosis Yes 515 11 90 4 605 10 
 No 4298 89 2123 96 6421 90 
Smoking in  0 3139 66 805 37 3944 60 
Pack years 1-20 1306 26 687 32 1997 27 
 21-40 331 7 509 23 840 10 
 >40 37 1 175 8 212 3 
BMI  Normal 1458 29 616 28 2074 29 
 Underweight 38 1 18 1 56 1 
 Overweight 2062 43 1125 51 3187 45 
 Obesity 1222 27 437 20 1659 25 
Age a, *  68 y ± 9 y 65 y ± 9 y  
HRT Ever 1229 26 - - 1229 26 
 Never 3584 84 - - 3584 84 
Abbreviations: BMD, bone mineral density; N, number; BMI, body mineral index; y, years; a, results 
reported in mean and standard deviation; *, age at inclusion; HRT, Hormone replacement therapy 
 
 
Study 3 
In study 3 we included data from HUNT1, HUNT2 and HUNT3 representing a total of 97087 
people, including 1080 cases of lung cancer (table 8). Only persons with an observation 
period < 1 year were excluded from the study. 
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Table 7: Baseline characteristics for the study population with available smoking status. 
The Hunt study 1864-2008.  
  Never smokers 
N = 38,656 
Former smokers 
N = 20,914 
Current smokers 
N = 26,894 
  CVD CVD CVD 
  Yes 
   
No 
   
Yes 
   
No 
   
Yes 
   
No 
   BMI* < 18.5 1  1  1  1  2  2  
 ≥ 18.5 – < 25.0 30  51  29  47  45  58  
 ≥ 25.0 – < 30.0 45  36  50  40  42  31  
 ≥ 30.0 23  13  20  12  12  9  
Sex Female 69  59  18  43  25  51  
 Male 31  41  82  57  75  49  
Chronic cough Yes  5  3  8  4  18  10  
with phlegm             
Smoking Light smoker - - 60  89  53  84  
 Heavy smoker - - 40  11  47  16  
Person years a 14.6 ± 8.3 14.1 ± 9.0 16.5 ± 7.8 
Age at inclusion a 44.2 ± 19.1 46.9 ± 17.2 42.4 ± 15.6 
CVD, cardio vascular disease; BMI, Body mineral index; N, numbers; *, kg/m2; a, mean and 
standard deviation; Figures are percentage of participants in each group. 
 
11. Study variables 
 
11.1. Outcome variables 
 
Lung cancer diagnosis and stage of disease 
In all three studies lung cancer diagnosis was based on traditional histological classification 
(World Health Organization. Histological Typing of Lung Tumours, from the 2nd edition in 
1981 to date). Lung cancer was classified as NSCLC and SCLC. Based on the TNM 
classification system for lung cancer (International Association for the Study of Lung Cancer, 
IASLC) the CRN has categorized lung cancer into non-metastatic and metastatic disease for 
Lung cancer – influence of comorbidity on incidence and survival. The Nord-Trøndelag Health study.  
41 
 
the whole period. No tumor invasion of organ or neighboring structures, no lymph node 
metastasis other than local lymph node metastasis was defined as non-metastatic disease. 
Patients with all other metastatic features, including organ and lymph node metastasis, were 
defined as metastatic disease.  
We have no information on treatment for patients recruited from the HUNT study and the 
NLCB registry. However, there are no guidelines recommending different treatment regimens 
for patients with or without DM. 
 
11.2. Exposure variables: 
 
Diabetes mellitus (study 1) 
In the HUNT study diabetes mellitus was defined by the answer “yes” to the question “Do 
you have or have you had diabetes”. Approximately 60 % answered this question either with 
yes or no. Based on the information about age of the patient, current use of medication and 
the duration of diabetes mellitus, the majority of the patients were classified as diabetes 
mellitus type II. In the PEG-study and the NLCB registry diabetes mellitus was diagnosed 
according to information of diabetes mellitus and/or the use of anti-diabetic medication in the 
hospital medical record. 
 
Bone mineral density (study 2) 
The bone mineral density (BMD) was measured in the non-dominant forearm using Single 
Energy X-ray Absorptiometry (SXA) (Osteometer DTX 100, Osteometer AS, Copenhagen). 
Measure point was 24 mm distal from the point where the distance between radius and ulna 
was 8 mm. 
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For all analyses we used the z-score. The z-score was calculated in 10 years intervals for male 
and female separately using following formula: z-score = (observed BMD – mean BMD) 
divided by with the standard deviation. 
The z-score was categorized into tertiles: low z-score, middle z-score and high z-score. 
 
Self reported fracture history 
The participants were asked about former fractures in the wrist, hip or vertebra. A total of 55 
052 (84%) persons answered this question. An affirmative answer to at least one of these 
questions was defined as a positive self reported fracture history. To avoid inclusion of high 
energy fractures, persons with fracture at the age 50 years or younger were excluded.  
 
Self reported osteoporosis 
Self reported osteoporosis was defined by an affirmative answer to one of these questions 
“Has your doctor ever said that you have osteoporosis” or “Do you have or have you had 
osteoporosis”. A total of 52 804 (81%) answered this question. 
 
Cardio vascular disease (study 3) 
The definition of CVD was based on baseline questionnaires in all three surveys. CVD was 
defined by the answer “yes” to one or more of these questions: “Do you have or have you had 
myocardial infarction?”, “Do you have or have you had angina pectoris?” or “Do you have or 
have you had stroke?”. Approximately all participants answered this question (99%).  
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12. Statistical methods 
 
Different statistical methods were used in the three studies. 
Study 1: the Chi-square test, Kaplan Meier method and the Cox regression model. 
Study 2: the Chi-square test, the logistic regression model and also the Cox regression model,  
Study 3: the Chi square test, the t-test and proportional hazard regression.  
In all studies both univariable and the multivariable regressions were performed. 
 
In all three studies two-sided tests were used and statistical significance was defined as P < 
0.05. The Hazard ratio (HR) and Odds ratio (OR) is reported with 95% confidence interval 
(CI). The Wald test was used to compare HR’s between different groups. 
Age, sex, smoking status and pack years were included as confounders in the different 
statistical models. 
Statistical analyses were performed using PASW version 19 (Predictive Analytics Soft Ware, 
IBM Corporation, New York 10589, USA) and in paper 3 also the statistical program R 
version 2.15.2 (2012-10-26) for Windows. 
 
12.1. Tests used 
 
Chi square test for independence, This test is used to test the association between to 
categorical variables. 
T-test or Student’s t-test, is a hypothesis testing in which the test statistics follows a Student’s 
distribution if the null hypothesis is supported.  The test is often used when testing whether 
two sets of continuous data are significantly different from each other. 
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The Kaplan-Meier method estimates the survival over time even when persons drop out or are 
studied for different length of time. The Log rank used in the Kaplan-Meier model is the 
hypothesis test to compare the survival distributions of two samples.  
Cox regression model is like the Kaplan Meier method an estimator for survival, but the 
model includes one or more covariates that may be associated with the survival time. 
The logistic regression model is a type of regression analysis used to assess the relationship 
between a dichotomous outcome and one or more covariates. 
Imputation is one method to handle missing data in data set. In the present study missing data 
were estimated by use of multiple imputation [136]. 
 
13. Approvals 
 
The Regional Committee for Medical and Health Research Ethics have approved the current 
study (REK# 2010/1081). All participants in HUNT have signed informed consent for use of 
their data in research also for merging data with other registry. 
 
14. Results  
 
14.1. Study 1 
 
Prolonged survival in lung cancer patients with diabetes mellitus 
We found 1677 cases of lung cancer in the HUNT study. From the PEG study we included 
436 lung cancer patients and from the NLCB study 210 patients with lung cancer. If the case 
of death was either unknown (n=77) or other than lung cancer (n=98) patients were excluded. 
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In total 6 of the 175 excluded lung cancer patients had diabetes mellitus. A total of 1677 lung 
cancer patient were included in the study, 78 patients with and 1599 without diabetes mellitus. 
In the HUNT study the Kaplan-Meier survival analysis showed a non-significant trend 
towards increased survival in lung cancer patients with diabetes mellitus compared to those 
without diabetes mellitus; median overall survival (OS) was 8.0 months (CI 95%: 5.1-10.9) 
and 5.0 months (CI 95%: 4.4-5.6) (p = 0.077), respectively. The 1-year, 2-year and 3-year 
survival for patients with and without diabetes mellitus were 33% vs. 28%, 13% vs. 8% and 
5% vs. 1%, respectively.  
In the PEG study The Kaplan-Meier survival analysis showed an increased 3-years survival in 
lung cancer patients with compared to patients without diabetes mellitus (p = 0.048). Median 
OS was 16.0 (CI 95%: 5.7-26.3) months and 7.1 (CI 95%: 6.3-7.8) months, respectively. The 
1-year, 2-year and 3-years survival for patients with and without diabetes mellitus were 53% 
vs. 31%, 21% vs. 12% and 0% vs. 0%, respectively. The Kaplan-Meier survival analysis 
showed equal 3-years survival in patients with and without diabetes mellitus (p = 0.93). 
Median OS was 14.0 (CI 95%: 8.2-19.8) months and 11.0 (CI 95%: 8.0-14.0) months 
respectively. The 1-year, 2-years and 3-years survival for patients with and without diabetes 
mellitus were 52% vs. 53%, 31% vs. 38% and 0% vs. 29%, respectively, (table 9).  
In a combined survival analysis in the HUNT- and PEG-study and NLCB registry the Kaplan-
Meier survival analysis showed an increased 3-years survival in lung cancer patients with 
diabetes mellitus compared to lung cancer patients without diabetes mellitus (p = 0.005) 
(figure 7). Median OS was 10.0 (CI 95%: 7.7-12.3) months compared to 6.0 (CI 95%: 5.6-
6.3) months.  The 1-year, 2-year and 3-year survival for patients with and without diabetes 
mellitus were 43% vs. 28%, 19% vs. 11% and 3% vs. 1%, respectively. 
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Table 8: Multivariate analysis (Cox regression) for survival in patients with lung cancer. 
 
 
Figure 6: Kaplan-Meier survival curve for patients with and without diabetes mellitus in 
the HUNT and PEG-study and NLCB registry all combined 
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14.2. Study 2 
 
Bone mineral density, fracture history, self reported osteoporosis as proxy 
variables for estrogen and the risk of Non-Small-Cell Lung Cancer – a 
population based cohort study, the HUNT study: are proxy variables friends or 
faults? 
A total of 9467 persons, 7254 (77 %) women and 2213 (23 %) men, were included in the 
study. In all 156 (1.6 %) persons developed NSCLC, 83 (1.1%) women and 73 (3.3%) men, 
which is in accordance with the life-time incidence of lung cancer in Norway. In both sexes 
those with low BMD z-score were at higher risk of NSCLC compared to those with high 
BMD z-score, both in unadjusted and adjusted models (men: OR 2.67, 95% CI: 1.39-5.16; 
women: OR 2.38, 95% CI: 1.09-5.18). In addition women with a medium BMD z-score were 
at higher risk (OR 2.40, 95% CI: 1.09-5.28) (figure 8 and 9).  
 
Figure 7: The risk of NSCLC in women with low, medium and high BMD 
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Figure 8: The risk of NSCLC in women with low, medium and high BMD 
 
 
 
In both sexes there were no associations between NSCLC diagnosis and self-reported fracture 
or self-reported osteoporosis (table 10). Sensitivity analysis including lung function and self 
reported lung symptoms did not change the estimates for BMD. 
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Table 9: Crude and adjusted odd ratio (OR) of NSCLC according to proxy variable 
BMD, self reported fracture and self reported osteoporosis, The HUNT study 1995-2008 
 Women Men 
 unadjusted Adjusted Unadjusted Adjusted 
 OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
 BMD z-score 
BMD              High 1 Reference 1 Reference 1 Reference 1 Reference 
Medium 1.76 0.98-3.16 2.40 1.09-5.28 1.65 0.83-3.30 1.64 0.81-3.31 
Low 1.90 1.07-3.38 2.38 1.09-5.18 3.28 1.73-6.21 2.67 1.39-5.16 
PY                        0 1 Reference 1 Reference 1 Reference 1 Reference 
1-20 4.21 2.49-7.13 4.03 2.12-7.67 1.89 0.85-4.21 1.79 0.81-4.00 
21-40 10.28 5.69-18.60 10.77 5.25-22.08 4.98 2.41-10.28 4.31 2.07-8.96 
>40 8.34 1.91-36.3 5.70 0.73-44.76 8.55 3.84-19.03 7.74 3.45-17.37 
BMI   Underweight 1.02 0.14-7.59 1.23 0.16-9.55 5.16 1.39-19.10 4.02 1.03-15.69 
                   Normal 1 Reference 1 Reference 1 Reference 1 Reference 
Overweight 0.49 0.29-0.81 0.79 0.44-1.41 0.83 0.48-1.41 1.01 0.58-1.76 
Obesity 0.54 0.31-0.95 0.70 0.33-1.49 0.67 0.32-1.38 0.78 0.37-1.64 
HRT 0.99 0.71-1.37 1.07 0.77-1.50 - - - - 
 Self reported fracture history 
Fracture yes 0.81 0.47-1.39 0.76 0.39-1.47 0.76 0.35-1.68 0.76 0.34-1.71 
PY                        0 1 Reference 1 Reference 1 Reference 1 Reference 
1-20 4.21 2.49-7.13 4.67 2.41-9.03 1.89 0.85-4.21 1.91 0.86-4.26 
21-40 10.28 5.69-18.60 12.70 6.12-26.38 4.98 2.41-10.28 4.75 2.28-9.88 
>40 8.34 1.91-36.3 6.63 0.84-52.2 8.55 3.84-19.03 8.56 3.83-19.13 
BMI   Underweight 1.02 0.14-7.59 1.25 0.16-9.69 5.16 1.39-19.10 4.03 1.04-15.63 
                   Normal 1 Reference 1 Reference 1 Reference 1 Reference 
Overweight 0.49 0.29-0.81 0.74 0.42-1.32 0.83 0.48-1.41 0.90 0.52-1.55 
Obesity 0.54 0.31-0.95 0.58 0.27-1.22 0.67 0.32-1.38 0.67 0.32-1.40 
Age 0.99 0.96-1.01 1.03 0.99-1.06 1.01 0.98-1.03 1.01 0.98-1.04 
HRT 0.99 0.71-1.37 1.03 0.73-1.46 - - - - 
 Self reported osteoporosis 
Osteoporosis yes 1.06 0.55-2.06 0.93 0.39-2.22 1.78 0.69-4.52 1.73 0.66-4.51 
PY                        0 1 Reference 1 Reference 1 Reference 1 Reference 
1-20 4.21 2.49-7.13 4.67 2.42-9.03 1.89 0.85-4.21 1.92 0.86-4.28 
21-40 10.28 5.69-18.60 12.69 6.11-26.33 4.98 2.41-10.28 4.74 2.28-9.86 
>40 8.34 1.91-36.3 6.59 0.84-51.87 8.55 3.84-19.03 8.57 3.83-19.16 
BMI   Underweight 1.02 0.14-7.59 1.29 0.17-9.98 5.16 1.39-19.10 3.86 0.99-15.08 
                   Normal 1 Reference 1 Reference 1 Reference 1 Reference 
Overweight 0.49 0.29-0.81 0.75 0.42-1.33 0.83 0.48-1.41 0.89 0.52-1.53 
Obesity 0.54 0.31-0.95 0.58 0.28-1.23 0.67 0.32-1.38 0.67 0.32-1.40 
Age a 0.99 0.96-1.01 1.03 0.99-1.06 1.01 0.98-1.03 1.01 0.98-1.04 
HRT 0.99 0.71-1.37 1.03 0.73-1.46 - - - - 
Abbreviations: OR, Odds ratio; CI, confidence interval; PY, pack years; BMI, Body mineral 
index; BMD, bone mineral density; a, age at inclusion; HRT, Hormone replacement therapy 
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14.3. Study 3 
 
Cardio vascular disease and the risk of lung cancer, the HUNT study 
During follow-up from 1984-2008, 1080 cases (1.1%) of lung cancer occurred (20% SCLC, 
80% NSCLC), 721 cases (1.5%) among men and 359 cases (0.7%) in women, p<0.001. The 
mean age at diagnosis of lung cancer was 70.2 ± 10 years for both sexes. The cumulative 
incidence of lung cancer in never smokers, former smokers and current smokers was 72 
(0.2%), 182 (0.9%) and 698 (2.6%) respectively, p<0.001. Missing smoking data was 
observed in 128 (1.2%). 
In never smokers, 37 cases of lung cancer / 100,000 person years were seen in those with 
CVD vs. 12 cases / 100,000 person years in those without CVD. In former and current 
smokers 280 cases of lung cancer / 100,000 person years were seen in those with CVD vs. 64 
cases of lung cancer / 100,000 person years in those without CVD. 
In univariate regression model CVD was not a statistically significant risk factor for lung 
cancer in never (HR: 1.04, 95% CI: 0.41-2.67), but statistically significant risk factor in 
former (HR: 2.47, 95% CI: 1.77-3.45) and current smokers (HR: 1.59, 95% CI: 1.26-2.01), 
(figure 10).  
In former and current smokers men were at a higher risk getting lung cancer compared to 
women (HR: 3.94, 95% CI: 2.59-5.97; HR: 1.86, 95% CI: 1.59-2.16 respectively for former 
and current smokers). In former and current smokers, chronic chough was a risk factor for 
lung cancer (HR: 2.19, 95% CI: 1.07-4.44; HR: 2.57, 95% CI: 2.08-3.18, respectively for 
former and current smokers). In former and current smokers heavy smokers were at a higher 
risk getting lung cancer compared with light smokers (HR: 8.61, 95% CI: 5.96-12.45; HR: 
6.01, 95% CI: 5.17-7.15, respectively for former and current smokers). 
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Figure 9: Plot of proportion “not getting lung cancer” by age for never smokers 
(n=38,656), former smokers (n=20,914) and current smokers (n=26,894), separately 
presented for persons with (n=5,981) and without CVD (n=80,483). The HUNT study 
1984-2008 
 
After adjustment for confounders the positive association found in the unadjusted model 
between CVD and the risk of lung cancer, disappears in never smokers. In former and current 
smokers CVD was still associated with a 1.4-1.7- fold increased risk getting lung cancer, 
(table 11 A-C). 
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Table 10: Cox regression model to analyze the association between CVD and lung 
cancer (A) never smokers (B) former smokers (C) current smokers 
A: 
Cox regression model to analyze the association between CVD and lung cancer in never 
smokers, adjusted for BMI, sex and chronic cough and phlegm, with age used as the time 
variable. N 33 121, 58 cases of lung cancer.  
 HR 95% CI p-value 
CVD 0,87 0,34-2,23 0,778 
BMI*    
< 18.5 4,57 0,60-34,76 0,142 
≥ 18.5 – < 25.0 1   
≥ 25.0 – < 30.0 2,13 1,16-3,92 0,0154 
≥ 30.0 1,03 0,39-2,69 0,958 
Sex    
male vs. female 2,34 1,37-3,96 0,0019 
Chronic cough with phlegm     
yes vs. no 2,51 0,78-8,09 0,1222 
 
B: 
Cox regression model to analyze the association between CVD and lung cancer in former 
smokers, adjusted for BMI, sex, burden of smoking and chronic cough and phlegm, with 
age used as the time variable. N 11 776, 102 cases of lung cancer.  
 HR 95% CI p-value 
CVD 1,74 1,11-2,73 0,016 
BMI*    
< 18.5 2,60 0,36-19,01 0,347 
≥ 18.5 – < 25.0 1   
≥ 25.0 – < 30.0 0,81 0,53-1,25 0,339 
≥ 30.0 0,80 0,43-1,48 0,473 
Sex    
male vs. female 1,43 0,82-2,49 0,206 
Chronic cough with phlegm    
yes vs. no 0,88 0,32-2,42 0,808 
Heavy vs. light smoker 3,56 2,33-5,45 <0,001 
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C: 
Cox regression model to analyze the association between CVD and lung cancer in current 
smokers, adjusted for BMI,  sex, burden of smoking and chronic cough and phlegm, with 
age used as the time variable. N 20 931, 521 cases of lung cancer.  
 HR 95% CI p-value 
CVD 1,38 1,04-1,83 0,024 
BMI*    
< 18.5 1,36 0,67-2,75 0,39 
≥ 18.5 – < 25.0  1   
≥ 25.0 – < 30.0 0,98 0,81-1,17 0,788 
≥ 30.0 0,89 0,65-1,23 0,494 
Sex    
male vs. female 1,09 0,90-1,31 0,390 
Chronic cough with phlegm 
yes vs. no 1,55 1,22-1,97 <0,001 
Heavy vs. light smoker 2,11 1,75-2,54 <0,001 
 
In former smoker the HR for CVD in cases with missing data for either chronic cough with 
phlegm or burden of smoking (N=6425) was 2.85 95% CI: 1.68-4.89 and in the analysis 
including missing cases and complete cases (N=18201) the HR 2.13 CI 95% 1.24-2.45. The 
estimates for HR for CVD was not significant different in these analyses, Wald test p=0.16. 
In current smoker the HR for CVD in cases with missing data for either chronic cough with 
phlegm or burden of smoking (N=4499) was 1.62 95% CI: 1.02-2.53 and in the analysis 
including missing cases and complete cases (N=25430) the HR 1.44 CI 95% 1.13-1.82. The 
estimates for HR for CVD was not significant different in these analyses, Wald test p=0.56. 
The results shows that the missing cases did not changed the estimates for CVD and the 
results were consistent in all groups. 
The third study shows that CVD is associated with a higher risk of lung cancer in former 
smokers and current smokers independent of the smoking burden, but not in never smokers. 
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15. Discussion 
 
We have studied the possible influence on incidence and survival of comorbidities in patients 
with lung cancer. 
 
15.1. Diabetes mellitus and lung cancer 
 
The overall survival in lung cancer patients with diabetes mellitus was borderline improved in 
the HUNT study, compared to patients without diabetes mellitus. This pattern was confirmed 
in the PEG study whilst corresponding results was not found in the NLCB study. When 
merging lung cancer patients from all three study populations, increased overall survival was 
found in lung cancer patients with diabetes mellitus, both in the univariate and multivariate 
analyses. In addition, the hazard ratio was consistent in all three studies and showed survival 
benefit in the diabetes population. There was no imbalance in known prognostic factors 
between the group with DM and without DM. 
Results from studies on the impact of diabetes mellitus on lung cancer prognosis are to date 
conflicting. One study showed an increased survival [76] three referred no change in survival 
[48, 75, 78] and two studies showed decreased survival [137, 138]. We did not design our 
study in order to investigate potential mechanisms behind our findings. Different explanations 
are possible. Patients with diabetes mellitus had less often metastatic LC disease, but this 
should have been adjusted for by inclusion of stage of disease in our analyses. In addition, 
increased survival in patients with diabetes mellitus was clearly demonstrated in the PEG 
study where all patients had advanced lung cancer. It can be argued that the survival benefit 
seen in patients with diabetes mellitus depends on more frequent and regular consultations 
that lead to an earlier diagnosis and thereby a survival benefit. However, the fact that the 
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survival benefit was even more pronounced among the patients in the PEG study, where only 
patients with advanced lung cancer were included, contradicts the view that frequent 
consultation leading to earlier diagnosis is the cause of increased survival. 
We found only one previous report of increased survival in patients with lung cancer and 
diabetes mellitus [76]. This report used x2 analysis and no multivariate analysis and the 
patient number (lung cancer and diabetes mellitus) was as low as 25. Their main focus was 
that long-standing diabetes mellitus was suggested to be associated with impeded neoplastic 
cell spread and metastasis. Three studies have shown decreased survival [48, 137, 138]. The 
first study was a recently published meta-analysis consisting of 97 studies including 
hospitalized patients based on either elevated fasting blood glucose (≥ 7 mmol/L), medical 
records that confirmed the use of anti-diabetics or diabetes mellitus. Patients diagnosed with 
diabetes mellitus were in a minority. The cause of high fasting blood glucose may have been 
numerous. The mean age was about 55 years, which is low compared to the median age of 70 
years of lung cancer patients that may represent a selection bias. About one third was 
followed for 2.9 years. The second study was a retrospective registry study of members of a 
private health system. Patients were black or white people and were included during a 3-years 
period and followed by two years follow up. The Charlson index of comorbidity was used and 
the authors did the same analyses as we did. Diabetes with end-organ damage showed an 
elevated adjusted HR of 1.4, (95% CI 0.2-2.72, p=0.33), which prohibited final conclusion to 
be drawn. The third study consisted of advanced lung cancer patients. Two research letters 
showed no association between diabetes mellitus, lung cancer and survival, but it is 
noteworthy that also the study of Hanbali showed that the frequency of metastasis was lower 
in patients with lung cancer and diabetes mellitus [75, 78]. This indicates that our 
observations may not be an incidental finding. 
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The studies and study reports we found in our literature research were based on a very 
different design and number of patients, and all have limitations that may have influenced the 
results. 
With the introduction of individualized treatment using targeted therapy, co-morbidity 
appears to be important to care about. This fact leads to the importance of precise 
characterization of both the tumor and host. One example on the important interaction 
between targeted treatment in lung cancer and co-morbidity is the introduction of IGF-1R 
(Insulin-like growth factor-1 receptor) inhibitors that have serious impact on glucose 
metabolism [139, 140]. 
The fact that patients with diabetes mellitus showed a lower frequency of metastatic diseases 
may partly explain the survival benefit in patients with diabetes mellitus, because the majority 
of the patients with lung cancer die of metastasis and not of the primary tumor. However, we 
adjusted for stage of disease in our analyses. Accordingly, this potential advantage can hardly 
explain the increased survival in patients with diabetes mellitus. 
It can be argued that the survival benefit seen in patients with diabetes mellitus as a result of 
more frequent and regular consultations that lead to an earlier diagnosis and survival benefit. 
However, the fact that the survival benefit was even more pronounced among the patients in 
the PEG study, where only patients with advanced lung cancer were included, weakens this 
argumentation of frequent consultation as the cause. 
 
15.2. Bone mineral density and lung cancer 
 
To our knowledge this is the first study investigating the association between BMD and 
incidence of lung cancer, having the opportunity to adjust for specific confounders. The 
association between estrogen and lung cancer is discussed in capture 6.1. According to our 
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hypothesis we expected a lower risk of lung cancer in the population with low BMD 
compared to patients with high BMD due to a lower estrogen level and subsequently a lower 
carcinogenic drive, we presumed. We hypothesis this both in men and women, since also in 
men BMD is a surrogate for estrogen, capture 6.3. 
Unexpectedly, we found that a low BMD z-score was strongly associated with a higher risk of 
lung cancer in both sexes. The findings remained unchanged after adjusting for smoking, BMI 
and lung function. After our knowledge there are no other studies investigating BMD and 
lung cancer. However the association between estrogen and lung cancer was discussed before. 
Studies investigating estrogen, hormonal replacement therapy (HRT) and the risk of lung 
cancer have shown conflicting results. Due to different designs, mainly inclusion of women, 
comparisons are difficult. Taioli et al showed an increased risk of adenocarcinoma in females 
using HRT [141]. Adami et al did not find any association between the use of HRT and the 
occurrence of lung cancer in a large cohort study [142]. Kreuzer et al showed that patients 
who had used oral contraceptives had reduced risk of lung cancer, but it was not the case in 
those who had used hormonal replacement therapy [143]. In contrast Rodriguez et al showed 
that hormonal replacement therapy reduced the risk of lung cancer, but this was not the case 
in former hormonal replacement therapy users [144]. Schabath et al showed a 36% risk 
reduction of lung cancer in women using hormonal replacement therapy, but this effect 
decreased with increasing pack years and disappeared in heavy smoker [145]. All these results 
from former studies include only females.   
According to our knowledge there is only one study analyzing the association between 
osteoporosis and lung cancer. McGlynn et al showed in a large cohort study from Denmark 
that, men and women younger than 70 years having osteoporosis had an increased risk for 
lung cancer compared to those without osteoporosis [95]. The authors argued that young 
patients with osteoporosis were more likely to smoke and suggested that this was the reason 
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for their results. As far as we know, this study could not answer this question due to lack of 
data on individual life style factors. 
McGlynn had not access on risk factors like smoking and used instead clinical diagnosis as a 
surrogate for smoking (emphysema) by using the International Classification of Diseases 
(ICD 10) code system. In addition the authors used the same code system to identify patients 
with osteoporosis and it is not exactly clear which criteria that were used for the diagnosis.  
 
Inflammation, osteoporosis and lung cancer 
Inflammation is found to play a role in osteoporosis. Interleukin promotes osteoclast 
activation and increases the rate of bone remodeling and bone loss [146]. Inflammation may 
also play a role in lung cancer development [147]. Both in animal and human studies it has 
been shown a sex difference in lung development, i.e. lung anatomy and physiology, 
respiratory function and lung toxicology [148, 149]. Further, smoking women are more 
susceptible to develop lung cancer compared to smoking  men. Apoptosis is an important part 
of the inflammatory process. Tesfaigzi et al showed a sex difference in the apoptotic 
mechanism by exposing mice to a lipopolysaccharide and measuring Bcl-2 gene expression 
(or activation), a regulator of apoptosis. The female mice recovered faster after the exposure 
compared to male mice. Further, the authors showed that there is a sex difference showing a 
higher level of interleukin 6 in bronchoalveolar lavage in male mice [150]. These factors may 
in part explain that there may be sex differences in the occurrence and susceptibility of 
developing lung cancer. 
 
Vitamin D, osteoporosis and lung cancer 
Nutrition plays an important role in bone health, especially calcium and Vitamin D. A 
prospective study from Finland showed an inversely association between Vitamin D and lung 
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cancer risk in females and younger participants but not for men [105]. However, Weinstein et 
al did not find any association between Vitamin D and the risk of lung cancer in smoking 
males [151]. Unfortunately, we have no access to vitamin D levels in our study. If vitamin D 
deficiency should explain our findings, we would expect that the result were equal in both 
study groups, because both low z-score and fracture should be associated with low vitamin D 
levels. It is known that there are genetic variations of the vitamin D receptor. In other cancer 
types, like colon cancer, there has been shown that the genetic variation at the VDR locus 
influences the risk of cancer [152]. It has been not studied yet if this genetic variation may be 
important in the development of lung cancer and might explain the sex difference. 
 
15.3. CVD and lung cancer 
 
The present study indicates that CVD is an independent risk factor for lung cancer in former 
and current smokers, with strongest associations in former smokers compared to current 
smokers. Adjusting for established risk factors for lung cancer like BMI, sex, clinical 
symptoms indicating chronical inflammation in the lower airways and the burden of smoking, 
weakened the associations, but CVD was still a risk factor for lung cancer. To our knowledge 
this is the first study investigating the association between CVD and the incidence of lung 
cancer. 
Chronic inflammation plays a key role in the underlying pathophysiology of both CVD and 
lung cancer, and could theoretically explain our findings. Chronic inflammation is associated 
with an increased cell turnover with the potential of generating genetic errors, as well as 
stimulating angio-neogenesis and apoptosis. Different types of chronic inflammatory diseases 
are associated with cancer. COPD is known to be a chronic inflammatory disease and is an 
independent risk factor for lung cancer [153-155]. Also other different types of cancer are 
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associated with general chronic inflammation. Ankylosing spondylitis is positively associated 
with kidney cancer [156] and local inflammation like inflammatory bowel disease is 
associated with a higher risk of colon cancer [157].  
CVD has a high prevalence among patients with lung cancer, about 23% [45] and chronic 
inflammation is associated with the development of CVD [158, 159]. We found a positive 
association between CVD and lung cancer in both former and current smokers, but not in 
never smokers in our population. A possible explanation may be that the chronic 
inflammation responsible for development of CVD is not alone an independent risk factor 
related to lung cancer development, but smoking and CVD may have an additive or 
synergistic effect. This inconsistence may also be explained by the fact that heavy former 
smokers tend to die before they get lung cancer. 
 
Because smoking causes both lung cancer and CVD our results could be confounded by the 
effect of smoking. Stratification by smoking status and adjustment for smoking burden (light 
and heavy smokers), did, however, not change the estimates. Nevertheless, residual 
confounding by tobacco smoking cannot fully be ruled out. 
Other confounders like alimentary factors like nutrition, vitamins and less physical activity 
and indoor air pollution may also contribute to the development of lung cancer [105, 160-162] 
and are not tested in our study. SCLC was more frequent in former and current smokers 
compared to never smokers, which is a well known fact. The inflammatory pathway or 
carcinogenesis may be different in SCLC and NSCLC. 
Concerning the interaction between the burden of smoking and CVD in former smokers, this 
may depend on bias related to self-reported smoking. Those with less education and/or heavy 
smokers are likely to report accurate number of cigarettes per day [163] and this is especially 
seen in former smokers [164]. 
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However, our observation in the current study showing that CVD in former and current 
smokers may provide an additional risk factor for lung cancer is noteworthy but not surprising 
given the high prevalence of CVD in patients with lung cancer compared with a lower 
prevalence of CVD in persons without lung cancer (23% vs. 10%). CVD has been shown as a 
risk factor for colorectal cancer, persons with CVD had nearly twice the prevalence of 
colorectal cancers [165]. Smokers with CVD may be at high risk developing lung cancer 
compared to smokers without CVD. If so is the case, it may have an implication for detection 
of lung cancer since a large proportion of the population is either current smoker or former 
smoker and CVD has a high prevalence among these. 
 
16. Other considerations 
 
Confounders 
A confounder is a variable that correlates (positive or negative) with both the dependent and 
independent variable. 
In all three studies of this PhD thesis potential confounders like medication and physical 
activity are not included into our models. This might have influence the results.  
Different studies have investigated the use of Metformin in patients with lung cancer. 
Metformin seems to prevent lung cancer carcinogenesis in mice [79]. Another study showed a 
decreased risk of cancer in general and also of lung cancer [166]. However, other studies 
showed no association between metformin and the risk of lung cancer [82]. Insulin seems to 
increase the risk of lung cancer possible via activation of the insulin-like growth factor [73]. 
Most of the patients in our study with diabetes had diabetes mellitus type II, so it is unclear 
whether our result can be transferred to patients with diabetes mellitus type I. 
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Bisphosphonate are a class of drugs that prevent bone loss. They have been used since the 
beginning of this century in a widely grad. 
Literature about the influence of bisphosphonates on the risk of lung cancer is rare, but 
several studies show that bisphosphonates influence on the progression of the disease. It is 
shown that bisphosphonates development of skeleton complications [167, 168]. The 
association between calcium intake and the risk of lung cancer is not well investigated. One 
study concluded that increased dietary calcium has a preventive effect on the development of 
lung cancer in non smoking women [169]. The HUNT 2 registry study does not have a design 
able to solve this question or give possible answers. We have to keep to the descriptive 
presentation.  Use of NSAID as well as statins may reduce the risk of lung cancer [18]  [170].  
Physical activity is associated with a lower risk of lung cancer [17].  
In the HUNT study there are questions about diabetic medication and activity. Unfortunately, 
the answers response among people developing lung cancer in our study were low for these 
questions (about 30% response on medication and about 40% on physical activity) and we did 
not include these data in our analyses. Probably is this low response rate not a random 
phenomenon, and in case would bias our results. 
 
17. Statistical considerations 
 
17.1. Missing data 
 
Missing data are unavoidable in large epidemiological studies and can undermine the validity 
of research results. Many different reasons can lead to missing data.  
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Some missing data can affect the results other does not. Another problem is that some 
variables may only have small number of missing but in combination the number of patients 
with some missing data can be large.   
Missing data are classified as: missing completely at random, missing at random and missing 
not at random.  
Generally it is not possible to know whether missing data are at random or not at random. 
Missing data not at random causes problems not those missing data at random. A frequent 
solution to deal with missing data is the complete case method, in which the analysis uses 
only observations with all variables present. 
The One-way sensitivity analysis is one way to deal with missing data. Results from a 
complete data set is compared to the same analysis but now with an additional variable 
included. If the results did not change substantial the “new” variable is not important for the 
calculation. 
Multiple imputation (MI) has been become in the last years a common approach in missing 
data analysis. Prerequisite for imputation is that data are missing at random. Imputation 
preserves all cases by replacing missing data with a probable value based on other available 
information. Once all missing values have been imputed, the data set can then be analyzed 
using standard techniques for complete data [171].  The results are combined using simple 
rules to yield estimates, standard errors, and p-values that formally incorporate missing-data 
uncertainty. Large-scale imputation can introduce bias and can introduce more bias than a 
complete case analysis if the imputation model does not fit the data well. For this reason, 
using multiple imputation it is recommend carrying out a complete case analysis in parallel 
[172]. 
If the results in the analysis with completely observed data (complete case method) is similar 
with the results analyzed with missing data, there are reasons to believe that missing data are 
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at random. Then, it is plausible that the missing observations are unlikely to influence the 
results. 
In study 1 and 2 we used the complete case method without imputation. 
In study 3 we used the maximum likelihood estimation to handle cases with missing data. In 
this study population we had a relatively high number of missing data regarding smoking 
status (19%), the burden of smoking (22%) and chronic cough with phlegm N=23013 
(21.5%). Questions on tobacco smoking were included in a follow-up questionnaire in 
HUNT1, whilst in HUNT2 and 3 these were included in the main baseline questionnaire.  
This influences the response rate; 78%, 98% and 97% in HUNT 1, 2 and 3 respectively. In 
total smoking status was known in 86,674 (81 %) persons. To deal with the high amount of 
missing data we used imputation for chronic cough with phlegm and burden of smoking. In 
never smoker the HR for CVD in cases with missing data for either chronic cough with 
phlegm or burden of smoking (N=2902) was 1.26 95% CI: 0.28-5.68 and in the analysis 
including missing cases and complete cases (N=36023) the HR 0.96 CI 95% 0.44-2.09. The 
estimates for HR for CVD was not significant different in these analyses, Wald test p=0.67. 
 
17.2. Combination of data from 3 different studies 
 
Pooling data from different independent studies is common and can be useful. It increases 
sample size and so statistical power. However pooling data can have some pitfalls, like the 
study populations can be quite different and therefore not comparable, and not all variables 
may be comparable, or at last, participants can be counted more than one time [173]. An other 
way handling different studies is a separately analyses and comparing the results. 
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In the first study on diabetes mellitus and survival in lung cancer we data from three studies 
were combined. The main reason for pooling the data was to increase the sample size  
and thus the power for the analyses. The three studies (HUNT-, PEG- and NLCB-study) 
recruited patients from the same geographical part in Norway (North- or South-Trøndelag in 
the middle of Norway) and can therefore subsequently compared. The studies represent 
different time periods. The HUNT-study included a cohort of persons over an extended time 
span where the prevalence of lung cancer was 1-3%.  The NLCB-study included patients 
suspected to have lung cancer with a prevalence of lung cancer of 73%. The PEG study 
included only advanced NSCLC (IIIB/IV). Extracting verified lung cancer patients that were 
treated after the same national guidelines should not introduce bias related to diagnoses or 
treatment. All participants in the HUNT, PEG study and NLCB-study are identified with an 
eleven digits national identification number that all Norwegians are given at birth or 
immigration. All data are linked by this key and no duplicate data is present in our dataset. 
 
17.3. The HUNT study, sample size, possible bias, variables and other 
considerations 
 
From 1984 to 2008 a total of 153545 persons have been invited to the HUNT study. This 
population is considered representative of the Norwegian population, but the county of Nord-
Trøndelag lacks larger cities, has a lower educational and income level, and the proportion of 
smokers is slightly below the mean in Norway. In all 126159 (82%) have participated. A non-
responder study showed a possible selection bias [174, 175]. The main reasons for non-
attendance for people aged 20–44 years was the lack of time and staying outside the county; 
from 45–69 the main reasons was being very busy, forgetting the invitation or not being 
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interested in the study. In the aged 70 and older, the main reasons for non-attendance was 
having regular follow-up in the health services or being immobilized due to disease [176].  
All data have been linked to our national cancer registry [133] with by law regulates 
nationwide registration of all cancers and to the Cause of death Register [177] what should 
ensure a high reliability and validity of the cancer diagnosis and other dates. 
 
18. Limitation of the studies 
 
Common limitations for all three studies were the limited information about medication, both 
daily medications but also lung cancer therapy and the data about smoking habit was not 
complete.   
 
 
18.1. Study 1 
 
Prolonged survival in lung cancer patients with diabetes mellitus 
A potential shortcoming is that we used a classification system that divided the lung cancer 
population in limited or advanced disease, however it was based on the TNM system. Further, 
we had no information about lung cancer- and type of diabetes mellitus treatment in the 
HUNT study. However, we have no reason to believe that the treatment indication and chosen 
therapy for lung cancer in the three studies differ between patients with and without diabetes 
mellitus during the study period. In Norway we practice very similar treatment indications 
and modalities for the lung cancer population in accordance to the national guidelines, both 
with and without diabetes mellitus. Performance status (PS) is a known prognostic factor, but 
was not registered in the HUNT study. Accordingly, PS was not incorporated in our analyses. 
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18.2. Study 2 
 
Bone mineral density, fracture history, self reported osteoporosis as proxy variables for 
estrogen and the risk of Non-Small-Cell Lung Cancer – a population based cohort study, 
the HUNT study: are proxy variables friends or faults? 
The limitations of the study are the predominance of women in each of the three study groups. 
For most of the lung cancer patients we did not have status about estrogen substitution 
therapy. 
BMD is the most reliable surrogate marker for life time estrogen exposure. This is the reason 
for not discussing fracture history and self reported osteoporosis here, but it is discussed in the 
paper 2. 
 
18.3. Study 3 
 
Cardio vascular disease and the risk of lung cancer, the HUNT study 
One limitation is the number of missing data (about 20%) regarding smoking status, pack 
years and data about chronic cough with phlegm. To deal with the amount of missing data we 
used imputation for chronic cough with phlegm and burden of smoking, knowing that this 
may be bias the results. However, the results showed that the missing cases did not change the 
estimates for CVD and the results were consistent in all groups.  
Further we have adjusted for confounders at baseline and not included changes during 
observation which might bias the results.  
 
Non-participants in the HUNT study had lower socio-economic status and a higher mortality 
than participants. In addition the prevalence of CVDs, diabetes mellitus and psychiatric 
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disorders were higher in non-participants [176]. This fact may bias the results in our three 
studies. 
 
19. Strengths of the studies 
 
In our study population with approximately 106 000 participants the prevalence of lung 
cancer (1.9%) is comparable to what is seen in western countries. The median age of the lung 
cancer patients in the HUNT study was 71 years and indicates good external validity of the 
present study. In addition to the large and representative study population, it consisted of a 
cohort from a well-defined geographical area, with a stable number of inhabitants and less 
migration and emigration of the people. The participation rate in the HUNT study was high, 
approximately 90, 70 and 50% in the three periods (inclusion waves), respectively. The 
HUNT-study represents a large database of information about different known risk factors 
and confounders for NSCLC, like tobacco smoking, BMI, lung function and HRT use. The 
long observation period, as well as a high mean age further strengthens our study results. At 
last, the use of our national cancer registry with forced nationwide registration of all cancers 
ensures a high reliability and validity of the cancer diagnosis. 
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20. Main conclusions of the studies 
 
• Lung cancer patients with diabetes mellitus seem to have an increased survival 
compared to lung cancer patients without diabetes. 
• Low bone mineral density is associated with a higher risk of lung cancer in men and 
women. 
• Cardio-vascular disease is found to be an independent risk factor for developing lung 
cancer in former and current smokers. 
 
21. Implications of the results for the future 
 
• The survival benefit in lung cancer patients with diabetes mellitus may justify that 
lung cancer patients with diabetes mellitus should get the same treatment as the other 
patients without DM (DM should not be a excluding factor for treatment).  
• Patients with low bone mineral density seem to have higher risk for LC and may be a 
potential candidate for inclusion in future screening trails.  
• Patients with a positive smoking history and cardio vascular disease have a higher risk 
for LC and may be candidates for inclusion in future screening trials. 
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Lung  cancer  has the  highest  mortality  of all  cancers.  Patients  with  early  stage  disease  have  the  best  cure
rates  and  that emphasizes  the  importance  of early  detection.  About  half  of  all non-small  cell lung  cancers
(NSCLC)  are  estrogen  receptor  positive.  The  impact  of  estrogen  and  its receptors  for  NSCLC  carcinogenesis
has  been  studied  but  is  still  unclear.  Low  estrogen  levels  are  associated  with  osteoporosis.  We  hypothesize
that  low  bone  mineral  density  (BMD),  a positive  history  of  fracture  or  self-reported  osteoporosis,  used  as a
proxy  variable  for  life  time  estrogen  exposure,  are  associated  with  a low  incidence  of NSCLC.  We  analyzed
data from  a cohort  study,  the  Nord-Trøndelag  Health  Study  2 (1995–1997)  linked  to  the  Norwegian  Cancer
Registry.  Using  the  logistic  regression  model  we calculated  the  odds  ratio  (OR)  with  a 95%  conﬁdence
interval  (CI)  for  the  risk  of  NSCLC  for  the  three  proxy  variables,  stratiﬁed  by  sex.  Participants  older  than  50
years  of  age, having  measured  bone  density  (N  = 18,156),  having  answered  the  questions  on self-reported
fracture  (N  =  37,883)  and  osteoporosis  (N  =  25,701)  and  known  body  mass  index  (BMI)  (N  = 29,291),  were
evaluated  for  inclusion.  In 6996  participants  all these  information  was  available  in addition  to tobacco
use,  and  in  women  also  hormonal  replacement  therapy  (HRT).  Lung  function  (FEV1 percent  of  predicted)
was  included  in  a sensitivity  analysis.  We  identiﬁed  132  (1.9%)  cases  of  NSCLC,  59  (1.2%) and  73  (3.3%)
cases  in  women  and  men,  respectively.  Low  BMD  was  associated  with  a higher  risk  of  NSCLC,  OR:  2.38,
95%  CI:  1.09–5.18  and  OR:  2.67,  95%  CI: 1.39–5.16  in women  and  men,  respectively.  No  association  was
found  between  the  two  other  proxy  variables  and  the  risk  of  NSCLC.  Inclusion  of  lung  function  in  the
model  did  not  change  the  results.  Contrary  to  our  hypothesis,  women  and  men  with  low  BMD  had  a
higher  risk  for  NSCLC.  In addition  the  study  demonstrates  that  the  risk  depends  on which proxy  variable
was  chosen,  and  we  may  ask:  are  proxy  variables  reliable?
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Lung cancer has the second highest incidence rate and the
highest mortality rate of all cancers [1]. Early detection followed
by surgery provides the best survival rates. This emphasizes the
importance of identifying new risk factors, in addition to known
∗ Corresponding author at: Department of Circulation and Medical Imaging, Fac-
ulty of Medicine, University of Science and Technology, P.B.: 8905 MTFS, 7491
Trondheim, Norway. Tel.: +47 90086043; fax: +47 72826717.
E-mail address: Peter.Hatlen@ntnu.no (P. Hatlen).
factors like age and tobacco smoking [2] that can be included in
future screening programs.
About half of all non-small cell lung cancers (NSCLC) are estro-
gen receptor positive [3,4]. The impact of estrogen and its receptors
for NSCLC carcinogenesis has been studied, and contradictory
results are published [5–9]. Low estrogen levels are associated with
osteoporosis [10–12]. Former studies have indicated that bone min-
eral density (BMD) in women  as well as in men, might reﬂect life
time estrogen exposure [13,14]. BMD  should therefore reﬂect total
estrogen exposure better than measured estrogen levels at one or
few previous occasions [11,13–18]. In women estrogen therapy
prevents bone loss after menopause. The prevalence of osteoporo-
sis increases in both sexes [19]. Accordingly BMD, self-reported
0169-5002/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
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osteoporosis and self-reported previous fractures might be used as
surrogate measures of life time estrogen exposure. BMD  has been
studied as a possible risk factor for cancer prostate, breast and colon
cancer [20–26]. Low BMD  is an important risk factor for fracture
[27–30]. A positive fracture history was not associated with the
risk of ovarian cancer but was associated with a decreased breast
and endometrial cancer risk [31,32].
Self-reported osteoporosis has good reproducibility, high speci-
ﬁcity, but low sensitivity compared to BMD  based osteoporosis
diagnosis [33].
Based on the current knowledge we anticipated that a lower
cumulative estrogen exposure is associated with a lower risk of
NSCLC in both sexes, and hypothesized that corresponding asso-
ciation could be found for surrogate measures of low estrogen
exposure as low BMD, self-reported fracture history or self-
reported osteoporosis, This hypothesis was studied in the second
survey of a large population based cohort study in Norway, the
Nord-Trøndelag Health Study (HUNT2).
2. Methods
2.1. Cohort
The HUNT study is a large population-based prospective cohort
study in Nord-Trøndelag, Norway, having collected data in three
surveys [34]. The county had about 127 000 inhabitants in 1996.
In total 65 237 people, age 20 or above, participated in HUNT2
(69% of invited). This population is thoroughly studied and is fairly
representative for the whole population in Norway. However, the
county, in the middle of Norway, has few larger cities, has a slightly
lower educational and income level, and the proportion of smok-
ers is slightly below the Norwegian mean. In the present study we
used data from HUNT2 (1995–1997) which were linked to lung can-
cer data from the Cancer Registry of Norway and the Death Cause
Registry of Norway at Statistics Norway [35].
The observation period was from the day of inclusion in the
HUNT2 survey until the event of lung cancer, death or the end of
the study at December 31st 2008, whichever occurred ﬁrst.
2.2. Outcome variable
2.2.1. Lung cancer
Lung cancer diagnosis was based on the classiﬁcation system
established by the World Health Organization (WHO) and was  his-
tologically veriﬁed (biopsy or cytology specimen) [36]. Estrogen
receptors have only been found in NSCLC, therefore persons with
small-cell lung cancer (SCLC) were excluded from the analyses. Nor-
wegian law dictates that all new cases of cancer must be registered
in the Cancer Registry of Norway.
2.3. Exposure variables
2.3.1. Bone mineral density
BMD  was measured, in the period from August 1995 to June
1997, in the non-dominant distal forearm using single energy X-
ray absorptiometry (SXA) (Osteometer DTX 100, Osteometer AS,
Copenhagen). Measure site was 24 mm proximal from the point
where the distance between radius and ulna was 8 mm.
BMD  was measured as part of two HUNT2 sub studies: the
Osteoporosis Study, inviting random samples of women born in
the periods 1911–1930, 1936–1945 and 1954–1963, and the Lung
Study, inviting a random sample of all participants, and those
with self-reported “ever had asthma, use of asthma medication or
asthma related symptoms during the last year” [37,38]. Sex speciﬁc
BMD  z-scores were calculated as (observed BMD  minus mean BMD)
divided by standard deviation (SD). Mean BMD  and SD were calcu-
lated at three years intervals. However two years intervals were
used during the ages of 48–62 years, due to increased bone loss
within this group. BMD  z-score were reported in tertiles deﬁning
low, medium and high z-scores.
2.3.2. Self-reported fracture history
The participants were asked about former fractures in the wrist,
hip or vertebra. A total of 55 052 (84%) persons answered this ques-
tion. An afﬁrmative answer to at least one of these questions was
deﬁned as a positive self-reported fracture history. To avoid inclu-
sion of high energy fractures, persons with fracture at the age 50
years or younger were excluded.
2.3.3. Self-reported osteoporosis
Self-reported osteoporosis was deﬁned by an afﬁrmative answer
to one of these questions “Has your doctor ever said that you have
osteoporosis” or “Do you have or have you had osteoporosis”. A
total of 52 804 (81%) answered this question.
2.4. Covariates
Potential confounders were evaluated by use of a Directed
Acyclic Graph (not shown) and included in logistic regression anal-
yses if they met  the criteria for being deﬁned as a confounder.
These were tobacco smoking (four categories: 0, 1–20, 21–40 and
>40 pack years), BMI  (four categories according to the WHO  crite-
ria; <18.5 kg/m2 = underweight, 18.5–24.9 kg/m2 = normal weight,
25–29.9 kg/m2 = overweight, ≥30 kg/m2 = obesity). In women hor-
mone replacement therapy (HRT) use, deﬁned as ever/never users,
was also included in the model. Persons invited to the lung study
also performed spirometry. In a sensitivity analysis, lung function
deﬁned by prebronchodilator forced expiratory volume in one sec-
ond/forced vital capacity ratio (FEV1/FVC ratio) (≤0.7/>0.7), was
included as confounder, data were eligible for 4246 cases (45%). In
analyses including BMD  we  did not adjust for age since BMD  z-score
was already adjusted for age. In analyses including self-reported
fracture history or self-reported osteoporosis, the age at inclusion
in the HUNT2 was included as a continuous variable in the model.
“Lung symptoms”, included in a sub-analysis, was deﬁned by a
positive answer to questions on asthma related symptoms.
Only participants older than 50 years, having measured bone
mineral density, having answered the questions on self-reported
fracture and osteoporosis, with known body mass index (BMI) and
tobacco use and in women  with known HRT status were included
in our study (Fig. 1).
2.5. Statistical analysis
All statistical analyses were stratiﬁed by sex. Logistic regression
was used to assess odds ratio (OR) with 95% conﬁdence interval
for developing NSCLC. Two-sided tests were used and statistical
signiﬁcance was deﬁned as P < 0.05. Lung function and self-reported
lung symptoms were included in the model as sensitivity analyses.
The Hazard function was  calculated by Cox regression models
using NSCLC as the deﬁned event, and BMD  z-score, self-reported
fracture history and self-reported osteoporosis as explorative vari-
ables, respectively. Included confounders were tobacco use, age at
inclusion (not when using BMD  z-score as the explorative variable),
BMI, and in women  HRT as well.
Interaction terms between all confounders, used in the model,
and the exposure variables were tested, as a product in the logistic
regression model.
To test the correlation between the explorative variables (BMD
z-score, self-reported fracture and self-reported osteoporosis) the
Chi-square test was  used.
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Included in the HUNT study
N = 65237
No BMD z-score available
N = 47081
Known BMD z-score
N = 18156
Unknown history about 
fracture and osteoporosis
N = 8689
Known BMD z-score and questioned about history of 
fracture and osteoporosis 
(Age >50y, known BMI and known tobacco history)
N = 9390
Men
N = 2183
Women
N = 7207
Cases of lung 
cancer
N = 59
Cases of lung 
cancer
N = 73
Unknown BMI
N = 77
Women
N = 4813
Unkown HRT 
status
N = 2441
Abbreviations: BMD, bone mineral density; N, number; BMI, body mass index; HRT, Hormone 
replacement therapy
Fig. 1. Selection of the study population. Abbreviations: BMD, bone mineral density; N, number; BMI, body mass index; HRT, hormone replacement therapy.
Statistical analyses were performed using PASW version 19 (Pre-
dictive Analytics Soft Ware, IBM Corporation, New York 10589,
USA).
2.6. Ethics
The Regional Committee for Medical and Health Research Ethics
have approved the current study (REK# 2010/1081).
3. Results
3.1. Incidence of NSCLC
In our study population 132 (1.9%) persons developed NSCLC,
59 (1.2%) women and 73 (3.3%) men. The mean age at diagnosis of
NSCLC was for women 68 ± 9 years and for men  72 ± 9 years and for
death of any cause for women 82 ± 7 years and for men  78 ± 8 years.
The mean age for hip fracture was 72 ± 7 years, for wrist fracture
63 ± 7 years and for vertebra fracture 69 ± 6 years (Table 1).
3.2. Correlations between BMD  z-score, self-reported fracture
and self-reported osteoporosis
Of all women reporting a former fracture, 43% had a low BMD
z-score, and of those reporting osteoporosis 45% had a low BMD
z-score. Of all men  reporting a former fracture, 37% had a low BMD
z-score, and of those reporting osteoporosis 48% had a low BMD
z-score.
3.3. The risk of non-small cell lung cancer adjusted for
confounders
Men  compared to women  and ever smokers compared to never
smokers were at signiﬁcant higher risk of developing NSCLC. Fur-
ther, underweight men  and women with a BMI  > 25 kg/m2 were at
increased risk of NSCLC in the unadjusted model.
In both sexes those with low BMD  z-score were at higher risk
of NSCLC compared to those with high BMD  z-score, both in unad-
justed and adjusted models. In addition women with a medium
BMD  z-score were at higher risk. In both sexes there were no asso-
ciations between NSCLC diagnosis and self-reported fracture or
self-reported osteoporosis (Fig. 2). Smoking was  an independent
risk factor for NSCLC (Table 2).
Sensitivity analysis including lung function as a confounder did
not change the estimates, but low numbers, 23 cases of NSCLC in
women and 67 cases in men, reduced the power, especially among
women. Statistical signiﬁcance was not reached in women but the
trend however, that a lower BMD  z-score is associated with a higher
risk of NSCLC, persisted.
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Fig. 2. Hazard function for the risk of NSCLC, adjusted for pack years, BMI, HRT (A–F) and in addition for age at inclusion (C–F). (A) BMD  z-score in men and (B) in women; (C)
self-reported fracture in men and (D) in women; (E) self-reported osteoporosis in men  and (F) in women. Abbreviations: BMD, bone mineral density; BMI, body mass index;
HRT,  hormone replacement therapy; NSCLC, non-small cell lung cancer.
We  did not ﬁnd any interaction between the confounders and
the exposure variables (data not shown).
3.4. Inclusion of lung symptoms in the logistic regression model
A total number of 725 (34%) women and 1568 (76%) men  spec-
iﬁed self-reported lung symptoms in the survey. We included
self-reported lung symptoms in the logistic regression models in
addition to tobacco use, BMI  and HRT (only in women). As shown
in Table 3 the inclusion of self-reported lung symptoms did not
change the results.
4. Discussion
4.1. Main ﬁndings
Low BMD  z-score was  strongly associated with increased risk
of NSCLC in both sexes. These ﬁndings remained unchanged after
adjusting for tobacco use, BMI  and in women, HRT. Sensitivity anal-
ysis including lung function as a confounder did not change the
estimates in men, in women the estimates were no longer signif-
icant but the pattern, that lower BMD  is associated with a higher
risk of NSCLC, was still present.
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Table 1
Characteristics of the study populations, The HUNT study, 1995–2008.
Women  Men  Total
N % N % N %
BMD  z-score
High 1601 33 747 34 2348 34
Medium 1590 33 774 35 2364 33
Low  1622 34 692 31 2314 33
Fractures
Yes  1083 23 268 12 1351 20
No  3730 77 1945 88 5675 80
Osteoporosis
Yes  515 11 90 4 605 10
No  4298 89 2123 96 6421 90
Tobacco use in
0 3139 66 805 37 3944 60
Pack  years
1–20 1306 26 687 32 1997 27
21–40 331 7 509 23 840 10
>40  37 1 175 8 212 3
BMI
Underweight 38 1 18 1 56 1
Normal 1458 29 616 28 2074 29
Overweight 2062 43 1125 51 3187 45
Obesity 1222 27 437 20 1659 25
Agea,b 68 y ± 9 y 65 y ± 9 y
HRT
Ever 1229 26 – – 1229 26
Never 3584 84 – – 3584 84
Abbreviations: BMD, bone mineral density; N, number; BMI, body mass index; y,
years; HRT, hormone replacement therapy.
a Results reported in mean and standard deviation.
b Age at inclusion.
No association between the risk of NSCLC and other measures of
bone strength as self-reported osteoporosis or self-reported frac-
tures was found, neither in men  nor in women.
Our hypothesis, that the surrogate variables for low estrogen
exposure like low BMD, self-reported fracture history or self-
reported osteoporosis, were associated with a lower occurrence of
NSCLC, was rejected.
Noteworthy, our results demonstrate that the choice of proxy
variable may  have important effects on the results. To our knowl-
edge this is the ﬁrst study to investigate three proxy variables of life
time estrogen exposure and its association to the incident of NSCLC,
and in the same study having registered speciﬁc confounders and
adjusted for them, like tobacco use, BMI  and HRT.
4.2. Estrogen and non-small cell lung cancer
An increasing numbers of studies show that estrogen is essential
in the bone metabolism also in men  [13,16,39–41]. It is demon-
strated in different studies that BMD  reﬂects the life-time estrogen
exposure over years in men  [13,42,43]. In studies analyzing the risk
of cancer BMD  was used as a marker for life-time estrogen exposure
[20,24]. Accordingly available literature provides good evidence for
the appropriateness of using BMD  as a proxy variable for long-time
estrogen exposure in men.
Earlier studies investigating estrogen, HRT and the risk of NSCLC
have shown conﬂicting results [5–8]. Studies on HRT included only
women. The fact that women and men  with low BMD  z-score and
women with medium BMD  z-score, show a higher risk of NSCLC
contradicts the assumption that estrogen inﬂuences the develop-
ment of NSCLC. This is in accordance with the results reported by
Adami et al. [5].
4.3. Osteoporosis and NSCLC
According to our knowledge there is only one study analyzing
the association between the diagnosis of osteoporosis and NSCLC.
In a large Danish registry study McGlynn et al. showed that men  and
women younger than 70 years with osteoporosis had an increased
risk of NSCLC compared to those without osteoporosis [44]. This is
in agreement with our results, but our results does not support that
tobacco use explains the entire association as indicated by McGlynn
et al.
In contrast to our population based study with available data on
life style habits like tobacco smoking, McGlynn included patients
admitted to the hospital, used the diagnosis of emphysema as
a surrogate measure of tobacco use and registry diagnosis of
osteoporosis based on unknown criteria, opposed to the objective
measure of BMD  used in our study.
4.4. Proxy variables
Proxy variables are increasingly being used on a wide basis in
epidemiological studies. BMD, history of fracture and self-reported
osteoporosis has been used in different studies as proxy variables
for long time estrogen exposure. Obviously, the three proxy vari-
ables reﬂect the estrogen exposure over time better than a single
estrogen measurement at an earlier random point in time. Like
other researchers we have no access to former estrogen levels and
we are therefore dependent on the variables mentioned above.
There is an association between BMD  and endogenous estro-
gen level in both sexes [10,12–14]. We  have identiﬁed only one
previous study investigating the association between self-reported
fracture and endogenous estrogen level. The EPIC-Oxford prospec-
tive cohort study found an inverse association between estradiol
and fracture risk in both sexes [45]. Cauley et al. showed that low
BMD is associated with a higher risk of fracture in men  and women
[46]. We  found no study investigating endogenous estrogen level,
BMD and self-reported osteoporosis. However, in our study popu-
lation we  conﬁrmed a highly signiﬁcant correlation between low
BMD  z-score and the reporting of osteoporosis in men  and women
and a positive correlation between BMD  z-score and the answer to
the question on self-reported fracture. The fact that BMD is a pre-
dictor for future fractures was the reason why we used fracture as
the second proxy variable [27–30]. At last, there was a positive cor-
relation between fracture history and reported osteoporosis. Based
on available literature and the good correlation between the three
proxy variable observed in our population, we assume that all three
proxy variables should be suitable as proxy variables for life-time
estrogen exposure. However, the associations to the occurrence of
lung cancer came out differently when comparing the three proxy
variables. Correlation and outcome differs from cause and out-
come, where possible interaction and unknown confounders must
be thought of. Therefore, the three proxy variables for estrogen
exposure used in our study may  also be proxy variables for other
factors related to bone formation or degradation. Such factors may
include vitamin D, vitamin A and physical activity, and these are not
studied in the present study. BMD  appears to be a good objective
measurement and proxy variable for life-time estrogen exposure,
but it is difﬁcult to rank the three proxy variables, and the two last
variables are less studied in the literature as well.
The mean age for debut of NSCLC and the mean age for debut of
fracture were approximately the same, and fractures may  therefore
not be recognized as a risk factor for NSCLC.
Self-reported lung symptoms did not inﬂuence the results for
any of the three proxy variables.
People with previous fracture history, low BMD z-score and
self-reported osteoporosis may  be more multi morbid than oth-
ers, and could therefore die before the development of lung cancer.
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Table 2
Crude and adjusted odd ratio (OR) of NSCLC according to proxy variable BMD (3 categories), self-reported fracture and self-reported osteoporosis: the HUNT study, 1995–2008.
Women Men
unadjusted adjusted unadjusted adjusted
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
BMD z-score
BMD
High 1 Reference 1 Reference 1 Reference 1 Reference
Medium  1.76 0.98–3.16 2.40 1.09–5.28 1.65 0.83–3.30 1.64 0.81–3.31
Low  1.90 1.07–3.38 2.38 1.09–5.18 3.28 1.73–6.21 2.67 1.39–5.16
PY
0  1 Reference 1 Reference 1 Reference 1 Reference
1–20  4.21 2.49–7.13 4.03 2.12–7.67 1.89 0.85–4.21 1.79 0.81–4.00
21–40  10.28 5.69–18.60 10.77 5.25–22.08 4.98 2.41–10.28 4.31 2.07–8.96
>40  8.34 1.91–36.3 5.70 0.73–44.76 8.55 3.84–19.03 7.74 3.45–17.37
BMI
Underweight  1.02 0.14–7.59 1.23 0.16–9.55 5.16 1.39–19.10 4.02 1.03–15.69
Normal  1 Reference 1 Reference 1 Reference 1 Reference
Overweight  0.49 0.29–0.81 0.79 0.44–1.41 0.83 0.48–1.41 1.01 0.58–1.76
Obesity  0.54 0.31–0.95 0.70 0.33–1.49 0.67 0.32–1.38 0.78 0.37–1.64
HRT  0.99 0.71–1.37 1.07 0.77–1.50 – – – –
Self-reported  fracture history
Fracture
Yes 0.81 0.47–1.39 0.76 0.39–1.47 0.76 0.35–1.68 0.76 0.34–1.71
PY
0  1 Reference 1 Reference 1 Reference 1 Reference
1–20  4.21 2.49–7.13 4.67 2.41–9.03 1.89 0.85–4.21 1.91 0.86–4.26
21–40  10.28 5.69–18.60 12.70 6.12–26.38 4.98 2.41–10.28 4.75 2.28–9.88
>40 8.34 1.91–36.3 6.63  0.84–52.2 8.55 3.84–19.03 8.56 3.83–19.13
BMI
Underweight  1.02 0.14–7.59 1.25 0.16–9.69 5.16 1.39–19.10 4.03 1.04–15.63
Normal  1 Reference 1 Reference 1 Reference 1 Reference
Overweight  0.49 0.29–0.81 0.74 0.42–1.32 0.83 0.48–1.41 0.90 0.52–1.55
Obesity  0.54 0.31–0.95 0.58 0.27–1.22 0.67 0.32–1.38 0.67 0.32–1.40
Age  0.99 0.96–1.01 1.03 0.99–1.06 1.01 0.98–1.03 1.01 0.98–1.04
HRT  0.99 0.71–1.37 1.03 0.73–1.46 – – – –
Self-reported  osteoporosis
Osteoporosis
Yes 1.06 0.55–2.06 0.93 0.39–2.22 1.78 0.69–4.52 1.73 0.66–4.51
PY
0  1 Reference 1 Reference 1 Reference 1 Reference
1–20  4.21 2.49–7.13 4.67 2.42–9.03 1.89 0.85–4.21 1.92 0.86–4.28
21–40  10.28 5.69–18.60 12.69 6.11–26.33 4.98 2.41–10.28 4.74 2.28–9.86
>40 8.34 1.91–36.3 6.59  0.84–51.87 8.55 3.84–19.03 8.57 3.83–19.16
BMI
Underweight  1.02 0.14–7.59 1.29 0.17–9.98 5.16 1.39–19.10 3.86 0.99–15.08
Normal  1 Reference 1 Reference 1 Reference 1 Reference
Overweight  0.49 0.29–0.81 0.75 0.42–1.33 0.83 0.48–1.41 0.89 0.52–1.53
Obesity  0.54 0.31–0.95 0.58 0.28–1.23 0.67 0.32–1.38 0.67 0.32–1.40
Agea 0.99 0.96–1.01 1.03 0.99–1.06 1.01 0.98–1.03 1.01 0.98–1.04
HRT  0.99 0.71–1.37 1.03 0.73–1.46 – – – –
Abbreviations:  OR, odds ratio; CI, conﬁdence interval; PY, pack years; BMI, body mass index; BMD, bone mineral density; HRT, hormone replacement therapy.
a Age at inclusion.
Table 3
Risk of NSCLC in the three study groups (BMD z-score, self-reported fracture and self-reports osteoporosis): results from the unadjusted and the adjusted regression model
included self-reported lung symptoms in the model. Stratiﬁed by sex. The HUNT study, 1995–2008.
Women Men
Not adjusted for
lung symptoms
Adjusted for lung
symptoms
Not adjusted for
lung symptoms
Adjusted for lung
symptoms
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
BMD z-score
High 1 Ref 1 Ref 1 Ref 1 Ref
Medium  2.40 1.09–5.28 2.77 1.22–6.33 1.64 0.81–3.31 1.95 0.89–4.23
Low  2.38 1.09–5.18 2.75 1.22–6.20 2.67 1.39–5.16 3.39 1.64–7.01
Fracture  history 0.76 0.39–1.47 0.81 0.42–1.58 0.76 0.34–1.71 0.90 0.40–2.02
Osteoporosis  history 0.93 0.39–2.22 1.12 0.47–2.65 1.73 0.66–4.51 1.68 0.64–4.41
Abbreviations:  OR, odds ratio; CI, conﬁdence interval; Ref, reference; BMD, bone mineral density.
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However, in our population the mean age of death was nearly the
same, about 82 years, which is about 12 year after the mean age of
debut of NSCLC.
4.5. Strengths and limitations
First, the registry variables in the present prospective cohort
show a high level of representativity and reliability. It proﬁts from
the high participation rate (69%). A non-responder study did not
ﬁnd support for a selection bias [47]. Second, HUNT2 represents
a large database of information about different known risk fac-
tors and confounders for NSCLC, like tobacco smoking, BMI, lung
function and HRT use. Third, the long observation period of approx-
imately 13 years, as well as a high mean age further strengthens
our study results. Fourth, the use of our national cancer registry
with forced nationwide registration of all cancers ensures a high
reliability and validity of the cancer diagnosis.
The limitations of the study are primarily that we have no infor-
mation about the estrogen receptor status of the NSCLC cases and
about the estrogen serum levels.
5. Conclusion
Our hypothesis that women and men  with high BMD z-score
show an increased risk of NSCLC was rejected. Most likely estro-
gen does not promote NSCLC development. Despite that proxy
variables are often used in epidemiologically studies, this study
demonstrates that the evaluation of the potential role of estrogen in
developing NSCLC depends on which proxy variable for long term
estrogen exposure was chosen. This reminds us of the limitations
of using proxy variables in epidemiological studies, and one may
question if they are friends or faults.
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Cardio vascular disease and the risk of lung cancer, the HUNT study 
T. Amundsen, P. Hatlen, S. Carlsen, O. Salvesen, A. Langhammer (Trondheim, Norway) 
 
Background: Inflammation is involved in both lung cancer (LC) and cardio-vascular disease 
(CVD). 
 
Aims: We hypothesize that CVD is an independent risk factor for LC. 
 
Methods: Data from the Nord-Trøndelag Health Study linked to the Norwegian Cancer and 
Death Cause Registry, analyses stratified by smoking. 97,087 persons (1,634,967 person years), 
never smokers n=38,656, former smokers n=20,914, current smokers n=26,894, follow-up 15 
years. The proportional hazard model (HR CI 95%) for CVD on LC incidence, adjusted for age, 
sex, BMI, burden of smoking and chronic cough.  
 
Results: LC = 1,080, cases (1.1%), CVD = 5,981 (6.9%). CVD vs LC in former smokers = HR 
1.74 (CI95% 1.11-273), current smokers = HR 1.38 (CI95% 1.04-1.83), never smokers = HR 
0.87 (CI95% 03.4-2.23),  
Table 1 
Former smokers HR CI 95% Current smokers HR CI 95% 
CVD 1,74 1,11-2,73   1,38 1,04-1,83 
BMI Below 18.5 2,60 0,36-19,01   1,36 0,67-2,75 
18.5-25 1     1   
25-30 0,81 0,53-1,25   0,98 0,81-1,17 
Above 30 0,80 0,43-1,48   0,89 0,65-1,23 
Sex (M vs F) 1,43 0,82-2,49   1,09 0,90-1,31 
Chronic cough with phlegm (Y vs No) 0,88 0,32-2,42   1,55 1,22-1,97 
Heavy vs light smoker 3,56 2,33-5,45 Heavy vs light smoker 2,11 1,75-2,54 
Association CVD and lung cancer, former and current smokers. HR, hazard ratio,  
 
 
Conclusion: CVD was an independent risk factor for lung cancer in former and current smokers. 
CVD may be a novel risk factor for lung cancer screening. 
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Questionnaire HUNT1 
Questionnaire 1 
For people 20 years old and over, both sexes 
HUNT 1  
  
Page 1 
INVITATION TO CHEST X-RAY EXAMINATION AND EXAMINATION OF 
BLOOD PRESSURE AND BLOOD SUGAR  
The chest x-ray examination is now coming to your district. This time the 
results are part of a larger health study. Please see the enclosed brochure for 
information about the study. 
You will find the time and location of the examination below. 
Please fill in the questionnaire on the other side of this paper and bring it to 
the examination. Bring an X-ray certificate, tuberculosis vaccination card or 
your employee medical card if you have one. 
It is important that you attend even if you have recently had your blood 
pressure and blood sugar measured and even if you are receiving 
treatment for high blood pressure or diabetes. 
Sincerely, 
National Mass Radiography Service 
Box 8155 Dep., Oslo 1 
County Medical Officer 
Health Council 
National Institute of Public Health 
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A. How is your health at the moment? 
(Put an X in only one box) 
Poor 
Not so good 
Good 
Very good 
B. During the past 12 months, have you visited any of the following: 
<yes, no> 
A general practitioner (district medical officer, doctor in private practice, house 
physician) 
A company physician 
A military doctor 
A doctor at hospital (without being hospitalized) 
Another doctor  
C. Have you been hospitalized during the last 5 years? <yes, no>  
D. Are you taking or have you taken medicine for high blood pressure?  
<yes, no>  
E. Do you have or have you had any of the following illnesses? <yes, no>
Diabetes 
Myocardial infarction (heart attack) 
Angina pectoris (chest pain) 
Stroke or cerebral haemorrhage  
F. Do you suffer from any long-term illness or injury of a physical or 
psychological nature that impairs your functioning in your everyday 
life? (Long term means that it has lasted or will last for at least one year.) 
<yes, no>   
 
If YES, would you describe your impairment as slight, moderate or 
severe? < slight, moderate or severe > 
Motor impairment  
Vision impairment 
Hearing impairment 
Impairment due to physical illness 
Impairment due to mental health problems  
G. Do you have any siblings? (living or deceased) <yes, no>  
If YES, has one or more of them ever had any of the following illnesses? 
<yes, no, don't know> 
Diabetes 
Heart attack/angina pectoris 
High blood pressure 
H. Thinking about your life at the moment, would you say that you by 
and large are satisfied with life, or are you mostly dissatisfied? 
(Put an X in only one box) 
Very satisfied 
Satisfied 
Somewhat satisfied 
Neither satisfied nor dissatisfied 
Somewhat dissatisfied 
Dissatisfied 
Very dissatisfied 
  
SEE THE PICTURE OF THE BLOOD PRESSURE MEASUREMENT IN THE 
ENCLOSED BROCHURE 
I. Have you ever had your blood pressure measured? <yes, no, don't 
know> 
If you answered NO, proceed to question M.  
J. In what year was your blood pressure last measured? <year, don't 
know> 
19___ Give year here (about)  
 
K. Where did you last have your blood pressure measured? 
(Put an X in only one box) 
At a general practitioner (district medical officer, doctor in private practice, 
house physician) 
At a company physician 
At a military doctor 
At a hospital 
At another doctor 
Don't know  
L. What was the result of the blood pressure measurement? 
(Put an X in only one box) 
Start or continue taking medicine for high blood pressure 
Go in for a follow-up examination, but not take medicine 
No follow-up examination and no medication necessary  
M. Which general practitioner would you prefer to be referred to if this 
health survey indicates that you should undergo a more thorough 
examination? 
Write the name of the doctor here ______________ 
No particular doctor <cross> 
  
ABOUT YOUR JOB 
N. Are you currently employed?  
(Put an X in only one box) 
Yes, full-time employment (not including housework) 
Yes, part-time employment (not including housework) 
Yes, full-time housework 
No, not employed  
O. If you are not in full-time employment, is the reason: 
(Put an X in only one box) 
Unemployment/redundancy 
Retirement or disability pension 
Education or military service 
Other reason 
  
IF YOU ARE EMPLOYED, PLEASE ANSWER THE NEXT TWO 
QUESTIONS 
P. Does your work involve a lot of stress and hassles? 
(Put an X in only one box) 
No, not at all 
Rarely 
Yes, a certain amount  
Yes, almost all the time  
 
 
 
Q. Do you decide how your work is planned? 
(Put an X in only one box) 
No, not at all 
A little 
Yes, for the most part 
Yes, I decide  
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Questionnaire HUNT2 
HUNT 2 Questionnaire 1 
For people 20 years old and over, both sexes 
Page 1 
Page one is a personal invitation to the screening with information on where and 
when to attend. The participants were asked to fill in the questionnaire at home and 
bring it with them to their examination. The screening nurse at the examination 
location was to ensure that all questions on page two were filled in, explain 
misunderstandings if necessary and help participants complete and correct the 
questionnaire.  
Page 2 
This questionnaire is an important part of the Health Study. Here you will find 
questions about previous illnesses and other important conditions regarding your 
health. Please complete the form and take it with you to the health examination. 
If any questions are not clear, leave them unanswered until you come to the 
examination where you can discuss them with the person on staff who examines you. 
All information you give will be treated in the strictest confidence. 
Several places on this questionnaire we ask you to give your age when an illness 
occurred. If you do not know exactly how old you were, give the age that is closest to 
what you think may be correct. 
When the results of the examination are available, there will be some people who 
need to be re-examined by their own doctor. If this is the case for you, you will be 
informed of this in a letter that we will send with your results. At the same time, your 
doctor will be sent your results. This is why in the section at the end of the 
questionnaire you are asked to give the name of your general practitioner, community 
doctor or health care centre where results are to be sent and possible follow-up 
examination are to be carried out. 
Sincerely, 
The Nord-Trøndelag Health Service - The State Health Examiners - The State 
Institute for Public Health 
THIS IS ABOUT YOUR HEALTH 
How is your health at the moment? (Put an X in only one box) 
Poor 
Not so good 
Good 
Very good 
RESPIRATORY DISORDERS 
Do you cough daily during periods of the year? <yes, no>   
If YES, answer the next two questions.  
Do you usually bring up phlegm when coughing? <yes, no>   
Have you had a cough with phlegm for periods of at least 3 months during each of 
the last two years? <yes, no>     
Have you had attacks of wheezing or breathlessness during the last 12 
months? <yes, no>   
Do you have or have you had asthma? <yes, no>  Age first time ____    
Do you use or have you used asthma medication? <yes, no>   
CARDIOVASCULAR DISEASES, DIABETES 
Have you had or do you have:           
Myocardial infarction (heart attack) <yes, no>  Age first time ____   
Angina pectoris (chest pain) <yes, no>  Age first time ____   
Stroke/brain haemorrhage <yes, no>  Age first time ____   
Diabetes <yes, no>  Age first time ____    
What was the result the last time your blood pressure was measured? (Put an X 
in only one box) 
Start or continue taking medicine for high blood pressure 
Go in for a follow-up examination, but not take medicine 
No follow-up examination and no medication necessary 
Have never had blood pressure measured 
Are you taking medication for high blood pressure? (Put an X in only one box) 
Currently taking medication 
Previously, but not now 
Have never taken it 
Has one or more of your parents or siblings had a myocardial infarction (heart 
attack) or angina pectoris (chest pains)? <yes, no, don’t know>   
METABOLISM 
Have you ever had:  
Hyperthyroidism (too high metabolism) <yes, no>  Age first time ____    
Hypothyroidism (too low metabolism) <yes, no>  Age first time ____   
Goitre <yes, no>  Age first time ____  
Other disease of the thyroid gland <yes, no>  Age first time ____    
Do you take or have you ever taken either of these medicines: 
Thyroxin <yes, no>  Age first time ____  
NeoMercazole <yes, no>  Age first time ____    
Have you had a thyroid gland operation? <yes, no>  Age first time ____    
Have you had radioiodine treatment? <yes, no>  Age first time ____    
 
 
 
 
MUSCULOSKELETAL DISORDERS 
During the last year, have you had pain and/or stiffness in your muscles and 
limbs that has lasted for at least 3 consecutive months? <yes, no> 
If NO, go on to the next section. 
If YES, answer the following questions: 
Where did you have pain and/or stiffness? <yes, no> 
Neck 
Shoulders 
Elbows 
Wrists, hands 
Chest/stomach 
Upper part of back 
Lumbar region 
Hips 
Knees 
Ankles, feet 
(If you had complaints in several areas for at least 3 months in the last year, put a 
circle around the yes-X for the complaint that lasted longest.) 
How long did the pain and/or stiffness last? (Answer for the area where it lasted 
the longest) 
If less than 1 year, give the number of months. ____ Number of months 
If 1 year or more, give the number of years. ____ Number of years 
Have these complaints reduced your ability to work during the last year? (Also 
applies to those working at home. Put an X in only one box.) 
No, not significantly 
To some degree 
Significantly 
Don’t know 
Have you been on sick leave due to these complaints during the last year? 
<yes, no, not working> 
Have the complaints caused you to reduce your leisure activities? <yes, no> 
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Has a doctor ever said that you have/have had any of the following diseases? 
<yes, no> 
Osteoporosis 
Fibromyalgia (fibrositis/chronic pain syndrome) 
Arthritis (rheumatoid arthritis) 
Degenerative joint disease (osteoarthritis) 
Bechterew's disease (AS) 
Other long-term skeletal or muscular diseases 
 
Have you ever had: <yes, no>  Age last time ____  
A fractured femur 
A fractured wrist or forearm 
Neck injury (whiplash) 
Injury that led to hospitalisation 
OTHER COMPLAINTS 
To what degree have you had the following complaints in the last 12 months? 
<not at all, slightly, very much> 
Nausea 
Heartburn/ acid regurgitation  
Diarrhoea 
Constipation 
Palpitations 
Breathlessness 
OTHER DISEASES 
Do you have or have you ever had: <yes, no>  Age first time ____  
Epilepsy  
Mental health problems for which you sought help 
Cancer 
Other long-term disease 
EVERYDAY TASKS 
Do you suffer from any long-term illness or injury of a physical or 
psychological nature that impairs your functioning in your everyday life? <yes, 
no>   
(Long-term means at least one year.) 
If YES, would you describe your impairment as slight, moderate or severe? 
<slight, moderate, severe> 
Motor ability impairment 
Vision impairment 
Hearing impairment 
Impairment due to physical illness 
Impairment due to mental health problems 
 
 
 
 
 
 
 
 
 
 MEN continue after this section 
TO BE ANSWERED BY WOMEN ONLY 
How many children have you had? <_____ Number of children> 
(Put 0 if you have had no children) 
If you have had children, answer these questions:  
How old were you when you had your first child? <Age _____> 
How old were you when you had your last child? <Age _____> 
(Do not answer if you have only had one child) 
How old were you when you started menstruating? <Age ____> 
(Put 0 if you have never menstruated) 
Continue to the next section  
SMOKING 
Did any of the adults where you grew up smoke indoors? <yes, no>   
After you were 20 years old, do you live or have you lived with a daily 
smoker(s)? <yes, no>   
How long are you usually in a smoky room each day? <Number of hours ____> 
(Put 0 if you are not usually in a smoky room) 
Do you smoke? <yes, no> 
Daily cigarette smoker? 
Daily cigar/cigarillo smoker? 
Daily pipe smoker? 
Have never smoked daily (Put an X)  
If you previously smoked, how long has it been since you stopped? <Number of 
years ____> 
If you, now or previously, smoke(d) daily, answer these questions: 
How many cigarettes do you or did you usually smoke daily? <Number of cigarettes -
____> 
How old were you when you started smoking? <Age ____> 
How many years in total have you smoked daily? <Number of years ____> 
COFFEE/TEA/ALCOHOL 
How many cups of coffee/tea do you drink daily? <Number of cups ____> 
(Put 0 if you do not drink coffee/tea daily) 
Brewed coffee 
Other coffee 
Tea 
Concerning alcohol, are you a non-drinker? <yes, no> 
How many times a month do you normally drink alcohol? <Number of times 
____> (Do not include low-alcohol beer. Put 0 if less than once a month.) 
How many glasses of beer, wine or spirits do you usually drink in the course of 
two weeks? (Do not include low-alcohol beer. Put 0 if less than once a month.) 
Beer <Number of glasses ____> 
Wine <Number of glasses ____> 
Spirits <Number of glasses ____>  
 
PHYSICAL ACTIVITY 
DURING LEISURE TIME 
How much of your leisure time have you been physically active during the last 
year? (Think of a weekly average for the year. Your commute to work counts as 
leisure time.)  
<Hours per week: None, Less than 1, 1-2, 3 or more> 
Low physical activity (no sweating/not out of breath)    
Vigorous physical activity (sweating/out of breath) 
AT WORK 
(For both paid or unpaid work) 
How would you describe your work? (Put an X in only one box) 
Mostly sedentary work (e.g. at a desk, on an assembly line) 
Much walking at work (e.g. delivery work, light industrial work, teaching) 
Much walking or lifting at work (e.g. postman, nurse, construction work) 
Heavy physical work (e.g. forestry work, heavy agricultural work, heavy construction 
work) 
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HOW DO YOU FEEL? 
In the last two weeks, have you felt: <no, a little, a good amount, very much> 
Confident and calm? 
Happy and optimistic? 
Have you felt: 
Nervous and restless? 
Troubled by anxiety? 
Irritable? 
Down/depressed? 
Lonely? 
Read each item below and place an X next to the reply that comes closest to how 
you have been feeling in the past week (only one X per item). Do not take too long 
over your replies; your immediate reaction to each item will probably be more 
accurate than a long, thought-out response. 
I still enjoy the things I used to enjoy 
Definitely as much 
Not quite so much 
Only a little  
Hardly at all 
 
I get a sort of frightened feeling as if something awful is about to happen 
Very definitely and quite badly 
Yes, but not too badly 
A little, but it doesn’t worry me 
Not at all 
 
I can laugh and see the funny side of things 
As much as I always could 
Not quite so much now 
Definitely not so much now  
Not at all 
 
Worrying thoughts go through my mind 
A great deal of the time 
A lot of the time 
Not too often 
Very little 
 
I feel cheerful 
Never 
Not often 
Sometimes 
Most of the time 
 
I can sit at ease and feel relaxed 
Definitely 
Usually 
Not often 
Not at all 
 
I feel as if I’m slowed down 
Nearly all the time 
Very often 
Sometimes 
Not at all 
 
I get a sort of frightened feeling like ‘butterflies’ in the stomach 
Not at all 
Occasionally 
Quite often  
Very often 
 
I have lost interest in my appearance  
Definitely 
I don’t take as much care as I should 
I may not take quite as much care  
I take just as much care as ever 
 
 
I feel restless as if I have to be on the move 
Very much indeed  
Quite a lot 
Not very much 
Not at all 
 
I look forward with enjoyment to things 
As much as I ever did 
Rather less than I used to 
Definitely less than I used to 
Hardly at all 
 
I get sudden feelings of panic 
Very often indeed 
Quite often 
Not very often 
Not at all 
 
I can enjoy a good book or radio or television programme 
Often 
Sometimes 
Not often 
Very seldom 
 
 
EDUCATION 
What is your highest level of education? 
Primary school 7-10 years, continuation school, folk high school 
High school, intermediate school, vocational school, 1-2 years high school 
University qualifying examination, junior college, A levels 
University or other post-secondary education, less than 4 years 
University/college, 4 years or more 
WORK 
What kind of work do you currently do? (One or more Xs) 
Paid work 
Self-employed 
Full-time housework 
Student, military service 
Unemployed, laid off 
Retired/on Social Security 
How many hours of paid work do you have a week? <Number of hours ____ > 
Do you work shifts, at night, or on call? <yes, no> 
IN GENERAL 
Thinking about your life at the moment, would you say that you by and large are 
satisfied with life, or are you mostly dissatisfied?  
(Put an X in only one box) 
Very satisfied 
Satisfied 
Somewhat satisfied 
Neither satisfied nor dissatisfied 
Somewhat dissatisfied 
Dissatisfied 
Very dissatisfied 
Which general practitioner would you prefer to be referred to if this health 
survey indicates that you should undergo a more thorough examination? 
Write the doctor’s name here__________________ 
Thank you for completing this questionnaire! 
And once again, Welcome to the examination! 
 
Appendix III 
 
 
 
 
Questionnaire HUNT3 
┌ ┬ ┐
 
HUNT 3 Questionnaire 1 
 
Health and daily life 
1. How is your health at the moment? 
Poor  Not so good  Good  Very good 
 
                                                                           Yes      No
2. Do you suffer from long-term (at least 1 
year) illness or injury of a physical or 
psychological nature that impairs your 
functioning in your daily life?  
 
 
 
 
 
If Yes, 
Would you describe your impairment as slight, 
moderate or severe? 
 Slight Moderate Severe 
Motor ability impairment    
Vision impairment    
Hearing impairment    
Impairment due to 
physical illness 
   
Impairment due to mental 
health problems    
 
 
3. Do you have physical pain now that has lasted 
more than 6 months?    
Yes  No 
 
4. How strong has your physical pain been during the 
last 4 weeks? 
No 
pain 
Very 
mild 
Mild Moderate Strong Very 
strong 
      
 
5. To what extent has your physical health or 
emotional problems limited you in your usual 
socializing with family or friends during the last 4 
weeks? 
Not at all 
Very 
little Somewhat Much 
Was not able to 
socialize 
     
 
Health services 
6. During the last 12 months, have you 
visited any of the following:  Yes No
General practitioner   
Another specialist outside the hospital   
Consultation w/ a doctor without being admitted     
            to the psychiatric out-patient dept.   
            to another hospital out-patient dept.   
Chiropractor   
Homeopath, acupuncturist, reflexologist, laying on 
of hands or other alternative treatment practitioner 
  
    
7. Have you been admitted to hospital in 
the last 12 months? 
   
 
Illness and Injury 
                                                                        Yes      No 
8. Have you had any kind of attack of 
wheezing or breathlessness during the 
last 12 months? 
  
 
9. Have you at any time during the last 5 
years taken medicine for asthma, 
chronic bronchitis, emphysema or 
COPD? 
  
 
10. Do you take or have you taken 
medication for high blood pressure?   
 
 
11. Have you had or do you have 
any of the following:  
(Put an X on each line) 
If Yes, how old 
were you the first 
time 
 Yes No Ex: (34 years old) 
Myocardial infarction 
(heart attack)     years old 
Angina pectoris (chest  pain)     years old 
Heart failure     years old 
Other heart disease     years old 
Stroke/brain haemorrhage     years old 
Kidney disease     years old 
 
Asthma     years old 
Chronic bronchitis, 
emphysema or COPD     years old 
 
Diabetes      years old 
   
Psoriasis     years old 
Eczema on hands     years old 
 
Cancer     years old 
 
Epilepsy     years old 
Arthritis (rheumatoid 
arthritis) 
    years old 
Bechterew’s disease     years old 
Sarcoidosis     years old 
   
Osteoporosis     years old 
Fibromyalgia     years old 
Degenerative joint disease 
(osteoarthritis) 
    years old 
   
Mental health problems 
you sought help for     years old 
 
12. Has it ever been verified that you had high blood 
sugar (hyperglycaemia)? 
     Yes     No 
If Yes, in what situation was this discovered the first 
time? 
At a health examination  While sick 
While pregnant  Other 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Injuries   
13. Have you ever had:  
 Yes No 
If Yes, how old were 
you the first time 
Ex: (34 years old) 
Hip  fracture     years old 
Fractured wrist/forearm     years old 
Fracture/compressed 
dorsal vertebrae?     years old 
Whiplash     years old 
 
Illness in immediate family 
14. Do your parents, siblings or children have, or 
have they had, the following illnesses? (one X per line)
 Yes No 
Don’t 
know
Stroke or brain haemorrhage before 
the age of 60    
Myocardial infarction (heart attack) 
before the age of 60    
    
Asthma    
Allergies/hay-fever/nasal allergies    
Chronic bronchitis, emphysema or 
COPD    
    
Cancer    
Mental health problems    
Osteoporosis    
Kidney disease (not kidney stone, 
urinary tract infection, urinary 
incontinence) 
   
    
Diabetes     
 
15. Have your parents’ siblings, your cousins or 
either of your grandparents been diagnosed with 
diabetes (type 1 or type 2)? 
 Yes  No  
 
How do you feel? 
16. In the last two weeks, have you felt: (one X per line) 
 No A little 
A good 
amount 
Very 
much 
Confident and calm     
Happy and optimistic     
Nervous and restless     
Troubled by anxiety     
Irritable     
Down/depressed     
Lonely     
 
17. Has anyone at any time in your life tried to 
oppress, degrade or humiliate you over an extended 
period of time? 
Yes  No 
 
 
Lifestyle 
Smoking Yes No 
18. Did any of the adults where you 
grew up smoke indoors? 
  
19. Did your mother smoke when you 
were growing up? 
  
 
20. Do you smoke? (Put an X in only one box) 
 No, I have never smoked  
        If you never smoked, skip to question 22  
 No, I quit smoking  
 Yes, cigarettes occasionally (parties/vacation, not daily)  
 Yes, cigars/cigarillos/pipe occasionally  
 Yes, cigarettes daily  
 Yes, cigars/cigarillos/pipe daily  
 
 
21A. Answer this if you smoke daily now or 
previously smoked daily:  
 1.  How many cigarettes do/did     
you usually smoke daily?  
Cigarettes 
pr day 
   
 2.  How old were you when you 
started smoking daily?  years old 
   
 3.  If you previously smoked 
daily, how old were you when 
you quit smoking? 
 years old 
 
21B. Answer this if you smoke/previously smoked 
occasionally, but not daily:  
 1. How many cigarettes do/did      
you usually smoke in a month?  
Cigarettes 
pr mo. 
   
 2. How old were you when you 
started smoking occasionally?  years old 
   
 3. If you previously smoked 
occasionally, how old were you 
when you quit? 
 years old 
 
22. Do you use, or have you used snuff? 
No, never  Yes, occasionally  
Yes, but I quit  Yes, daily  
       If you answered No, never, skip to question 23 
 
If Yes, 
How old were you when you began using snuff? 
   years old 
 
How many portions snuff do/did you use a month? 
  Portions snuff a month 
   
If you use(d)/smoke(d) both cigarettes and snuff, 
which did you begin with first? 
Snuff  About the same time  (within 3 months)  
Cigarettes  Don’t remember 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Did you begin using snuff to try to quit or cut down 
on smoking?  
No    
Yes, to quit smoking  Yes, to cut down on smoking  
 
Diet 
23. How often do you normally eat these foods? 
       (one X on each line) 
 0-3 
times a 
month 
1-3 
times 
a 
week 
4-6 
times 
a 
week 
Once 
a  day
Twice or 
more a 
day 
Fruits, berries      
Vegetables       
Chocolate/candy      
Boiled potatoes      
Pasta/rice      
Sausages/hamburgers      
High-fat fish on bread 
or for dinner  (salmon, 
trout, herring, 
mackerel, haddock) 
     
24. Do you take the following dietary supplements? 
      (One X for each supplement) 
 Yes, daily Occasionally No 
Cod-liver oil    
Omega-3 capsules    
Vitamins and/or 
minerals     
 
25. How many glasses do you usually drink of the 
following?       ½ litre = 3 glasses (one X on each line) 
 Seldom/ 
never 
1-6 
gl. a 
week 
1 gl. 
a day 
2-3 
gl. a 
day 
4 gl or 
more   
a day 
Water, Farris, etc.      
Whole milk 
(sweet/sour) 
     
Other milk 
(sweet/sour) 
     
Soda/juice w/sugar      
Soda/juice w/out 
sugar      
Juice or nectar      
 
26. How many cups of coffee do you drink a day? 
      (write  0 if you do not drink coffee/tea daily) 
 Boiled coffee  
Other 
coffee  Tea   
  Number of 
cups       
 
27. How many cups of coffee do you drink in the 
evening (after 6pm)? 
       Number of cups  
 
 
 
Alcohol  
28. About how often in the last 12 months did you 
drink alcohol? (do not include low-alcohol beer) 
4-7 times a week  About once a month 
2-3 times a week  A few times a year 
About once a week  Not at all the last year 
2-3 times a month  Never drink alcohol 
 
29. Did you drink alcohol during the last 4 weeks? 
                    Yes  No  
  If Yes, 
  Did you drink so much that you felt very intoxicated 
(drunk)?  
No  Yes, 1–2 times  Yes, 3 times or more 
 
30. How many glasses of beer, wine or spirits do 
you usually drink in the course of two weeks: (do not 
include low-alcohol beer, write 0 if you do not drink alcohol) 
 Beer  Wine  Spirits  
  Number of glasses       
 
31. How often do you drink 5 glasses or more of 
beer, wine or spirits in one sitting? 
Never  Monthly  Weekly  Daily 
 
Exercise 
By exercise we mean going for walks, skiing, 
swimming and working out/sports. 
 
32. How often do you exercise? (on the average) 
Never  
Less than once a week  
Once a week  
2-3 times a week  
Nearly every day  
 
33. If you exercise as often as once or several times a 
week: How hard do you exercise? (average) 
 
I take it easy, I don’t get out of breath or break 
a sweat 
 
I push myself until I’m out of breath and break 
into a sweat 
 
I practically exhaust myself  
 
34. For how long do you exercise each time?(average) 
Less than 15 minutes  30 min.-1 hour  
15-29 minutes  More than 1 hour  
35. Do you have at least 30 minutes of physical 
activity daily at work or in your leisure time?        
 Yes  No  
 
36. About how many hours do you sit during a 
normal day? (include work hours and leisure time) 
     hours 
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Employment 
37. If you have had paid or unpaid employment, how 
would you describe your job?      (One X only) 
Work that mostly involves sitting (ex: desk work, 
assembly worker) 
 
  
Work that requires much walking (ex: clerk, light 
industry worker, teacher)  
  
Work that requires much walking and lifting 
 (ex: mail carrier, nurse, construction worker)  
  
Heavy physical labour (ex: forester, farmer, heavy 
construction worker)  
 
Height/Weight 
38. About how tall were you at age 18?  
 
    
  
 
 
cm 
 
Don’t remember 
 
 
 
39. About how much did you weigh at age 18? 
 
     
  
 
 
kg 
 
Don’t remember 
 
 
 
40. Are you satisfied with your weight now? 
Yes  No, don’t weigh enough  No,  weigh too much  
 
41. Have you tried to diet in the last 10 years?  
No  Yes, a few times  Yes, many times  
 
42. Do you weigh at least 2 kg less than you did 1 
year ago? 
Yes  No    
   
     If Yes, what is the reason for this? 
 Dieting  Illness/stress  Don’t know  
     
Serious events in the last 12 months 
43. Has a member of your immediate family died? 
     (Child, spouse/partner, sibling or parent)  
 Yes  No  
 
44. Have you been in imminent mortal danger 
because of a serious accident, catastrophe, violent 
situation or war? 
 Yes  No  
 
45. Has your relationship with your spouse or long-
term partner ended? 
 Yes  No  
 
46. If you answered Yes to one or more of the above 
questions (43, 44 or 45), how much have you reacted 
to this in the last 7 days?  
Not at all  Moderate amount  
A little  Very much  
    
 
 
 
 
Childhood – When you were 0-18 years old 
47. Who did you grow up with?  
Mother   Other relatives  
Father   Adoptive parents   
Stepmother/ 
stepfather   Foster parents  
 
48. Did your parents leave each other, or get a 
divorce, when you were a child? 
No   
Yes, before I was 7 
years old  Yes, when I was 7-18 years old 
 
49. Did either of your parents die when you were a 
child? 
No  
Yes, before I was 7 
years old  Yes, when I was 7-18 years old 
 
50. Did you grow up with pets? 
No  
Yes, 
cat  Yes, dog  Yes, horse  Yes, other animal 
 
51. How much milk or yoghurt did you usually drink? 
Seldom/ 
never 
1-6 
glasses 
pr. week 
1 glass 
pr. day 
2-3 
glasses  
pr. day 
More than 
3 glasses 
pr. day 
     
 
52. Did you grow up on a farm      
with farm animals? Yes   No 
 
53. When you think about your childhood, would you 
describe it as: 
Very good  Average  Very difficult 
Good  Difficult    
 
In General 
54. Thinking about your life at the moment, would you 
say that you by and large are satisfied with life, or are 
you mostly dissatisfied? (One X only) 
Very satisfied  
Satisfied  
Somewhat satisfied  
A bit of both  
Somewhat dissatisfied  
Dissatisfied  
Very dissatisfied  
 

